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Extended Epigenome
Abstract
AID/APOBEC family cytosine deaminases canonically play crucial roles in immunity by converting
cytosine to uracil in single-stranded DNA (ssDNA). Outside of this established physiological role, AID/
APOBEC enzymes have also been implicated in the poorly-understood process of DNA demethylation
through their proposed deamination of epigenetically-modified cytosine bases like 5-methylcytosine (mC)
and 5-hydroxymethylcytosine (hmC). However, there has been no thorough biochemical characterization
of AID/APOBEC activity on these substrates, or on the recently-discovered 5-formylcytosine (fC) and
5-carboxylcytosine (caC) to inform this proposed role. Here, we provide the first steady-state kinetic
measurements of the most active family member–APOBEC3A(A3A)–against various natural and
unnatural modified substrates using a novel, restriction enzyme-based deamination assay. We determined
that A3A has poor activity against bulkier oxidized cytosines, such as hmC, fC, and caC, and therefore
likely does not contribute substantially to active DNA demethylation via deamination of these bases. By
contrast, A3A efficiently deaminates mC in a manner not fully explained by the steric discrimination
observed with other AID/APOBEC family members.
Because A3A exhibits enzymatic proficiency for C and mC but potently discriminates against ox-mCs in
vitro, we hypothesized that we could leverage A3A’s biochemical properties to efficiently localize ox-mCs
in the genome. We developed APOBEC-Coupled Epigenetic Sequencing (ACE-Seq) – a nondestructive
alternative to bisulfite-based methods for base resolution localization of hmC. We first validated this A3Abased method on differentially-modified phage genomes to demonstrate efficient conversion of C/mC
and protection of hmC on a genome scale. We next applied ACE-Seq to mouse embryonic stem cell DNA
and found a striking correlation with published hmC data from bisulfite-based methods. We also
sequenced sorted mouse glutamatergic neurons and, using >100-fold less, saw significant correlation
with previously published TAB-Seq data from unsorted mouse cortex DNA. Finally, we demonstrate the
applicability of nondestructive ACE-Seq to locus-specific analysis with longer (>1 kb) amplicons, which
could permit clustering analyses on single reads from larger regions such as enhancers. Altogether, we
propose ACE-Seq as a facile alternative to bisulfite-based hmC localization methods, especially for
analyzing limiting DNA samples, such as those from small or transient cell populations.
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ABSTRACT

DEFINING AND EXPLOITING THE CYTOSINE DEAMINASE ACTIVITY OF APOBEC3A
ON THE EXTENDED EPIGENOME
Emily K. Schutsky
Rahul M. Kohli, M.D., Ph.D.

AID/APOBEC family cytosine deaminases canonically play crucial roles in immunity by
converting cytosine to uracil in single-stranded DNA (ssDNA). Outside of this established
physiological role, AID/APOBEC enzymes have also been implicated in the poorly-understood
process of DNA demethylation through their proposed deamination of epigenetically-modified
cytosine bases like 5-methylcytosine (mC) and 5-hydroxymethylcytosine (hmC). However, there
has been no thorough biochemical characterization of AID/APOBEC activity on these substrates,
or on the recently-discovered 5-formylcytosine (fC) and 5-carboxylcytosine (caC) to inform this
proposed role. Here, we provide the first steady-state kinetic measurements of the most active
family member–APOBEC3A(A3A)–against various natural and unnatural modified substrates
using a novel, restriction enzyme-based deamination assay. We determined that A3A has poor
activity against bulkier oxidized cytosines, such as hmC, fC, and caC, and therefore likely does
not contribute substantially to active DNA demethylation via deamination of these bases. By
contrast, A3A efficiently deaminates mC in a manner not fully explained by the steric
discrimination observed with other AID/APOBEC family members.
Because A3A exhibits enzymatic proficiency for C and mC but potently discriminates
against ox-mCs in vitro, we hypothesized that we could leverage A3A’s biochemical properties to
efficiently localize ox-mCs in the genome. We developed APOBEC-Coupled Epigenetic
Sequencing (ACE-Seq) – a nondestructive alternative to bisulfite-based methods for base
resolution localization of hmC. We first validated this A3A-based method on differentiallyiv

modified phage genomes to demonstrate efficient conversion of C/mC and protection of hmC on
a genome scale. We next applied ACE-Seq to mouse embryonic stem cell DNA and found a
striking correlation with published hmC data from bisulfite-based methods. We also sequenced
sorted mouse glutamatergic neurons and, using >100-fold less input DNA, saw significant
correlation with previously published TAB-Seq data from unsorted mouse cortex DNA. Finally,
we demonstrate the applicability of nondestructive ACE-Seq to locus-specific analysis with
longer (>1 kb) amplicons, which could permit clustering analyses on single reads from larger
regions such as enhancers. Altogether, we propose ACE-Seq as a facile alternative to bisulfitebased hmC localization methods, especially for analyzing limiting DNA samples, such as those
from small or transient cell populations.
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CHAPTER 1: Introduction
1.1

The AID/APOBEC family of cytosine deaminases

1.1.1

Canonical functions of cytosine deamination
The AID/APOBEC family of cytosine deaminases spans the vertebrate lineage from

lamprey to human, and all family members share the ability to catalyze the hydrolytic
deamination of cytosine to form uracil in single-stranded nucleic acid substrates (Figure 1-1). The
first discovered family member, apolipoprotein B mRNA editing catalytic polypeptide-like 1
(APOBEC1), physiologically targets RNA – specifically, it uses a precise CU mutation to
create a premature stop codon in the mRNA encoding apolipoprotein B to allow translation of a
small intestine-specific truncated apolipoprotein (ApoB48) in place of the liver-specific fulllength counterpart, ApoB100 (Navaratnam et al., 1993; Teng et al., 1993). All other known
APOBECs with validated biochemical activity (i.e. all except for APOBEC2 and APOBEC4,

Figure 1-1. Reaction mechanism of AID/APOBEC deamination
AID/APOBEC-catalyzed deamination relies on a catalytic base (aspartate or glutamate) to
deprotonate a water molecule, allowing for nucleophilic attack at the 4-carbon of the cytosine
ring. After generating a tetrahedral intermediate, the original amine at the 4-position is released
as ammonia, leaving a ketone at the 4-position.

which have no currently ascribed functions) are believed to target single-stranded DNA substrates
physiologically, and even APOBEC1 shows a preference for DNA over RNA in vitro (Harris et
al., 2002; Petersen-Mahrt and Neuberger, 2003; Nabel et al., 2013). Canonically, these DNAspecific reactions play roles in both innate and adaptive immune contexts. Activation-induced
deaminase (AID), the most ancestral member of the family with paralogues in jawless fish,
specifically generates uracils in host genomic DNA. AID targets the immunoglobulin genomic
locus for mutation in order to promote antibody maturation via somatic hypermutation and class1

switch recombination through coordinated repair of the uracil lesions (Maul and Gearhart, 2010).
The mammalian-specific APOBEC3 subfamily physiologically targets foreign genomes and thus
contributes to the restriction of retroviruses and endogenous retroelements (Refsland and Harris,
2013). Whereas some species, including mice, have only one APOBEC3 enzyme, primates and
humans encode seven different subfamily members (APOBEC3A – APOBEC3H) that likely
arose through multiple gene duplication and specification events in response to intense
evolutionary pressure (Jarmuz et al., 2002). One family member, APOBEC3G, serves as the
specific ubitquitylation target of the HIV Vif protein, and can effectively restrict HIV strains
lacking Vif (vif) (Lecossier et al., 2003; Mangeat et al., 2003; Zhang et al., 2003). Other
APOBEC3s have been found to specifically restrict certain viruses (such as HBV, herpesvirus,
etc.) and/or genomic retroelements (reviewed in (Refsland and Harris, 2013), though it remains
unclear whether some family members perform redundant functions or whether each recognizes
its own set of viral substrates.
This thesis work specifically focuses on some of the proposed alternative
targets/activities of AID/APOBECs, distinct from their canonical functions in immunity. As such,
the rest of the introduction to this work will describe known and proposed alternative activities of
and uses for AID/APOBECs—in oncogenic mutation, in DNA demethylation, and in genome
modification—in order to illustrate specific structure/function aspects of this enzyme family. The
first section of this introduction will frame this thesis by broadly conveying the importance of
AID/APOBECs outside of their canonical roles in immunology while simultaneously offering a
description of known aspects of their biochemical mechanism. The second section of this
introduction will then address the topic of epigenetic modifications of cytosine bases, specifically
focusing on what remains unknown about their specific localizations and functions based
primarily on the lack of feasible, affordable, and reliable methods to map them at base resolution.
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1.1.2

Proposed alternative activities for AID/APOBEC-catalyzed deamination
1.1.2.1 Oncogenic mutation
Cytosine deamination, when unrepaired, results in a transition mutation after replication

(C:G  A:T). When DNA deaminase activity is mistargeted, the accumulation of undesired
mutations in the host genome could contribute to oncogenic transformation. Because AID is the
only AID/APOBEC whose physiological activity is on the host genome, it is not surprising that
the first reported cases of deamination-induced oncogenesis were B-cell lymphomas caused by
erroneous AID activity in B cells outside of the immunoglobulin loci that led to myc/IgH
translocations (Ramiro et al., 2004). Further sequencing studies confirmed the role of AID in
many oncogene/Ig translocation events (Klein et al., 2011). In contrast to AID, the APOBEC3s
are known to be tightly regulated and typically cytoplasmic; as such, the APOBEC3 enzymes are
thought to exclusively target non-host ssDNA exposed during processes like reverse transcription
and were therefore thought to be less likely to act on host genomic DNA and to cause oncogenic
transformation. Therefore, it was thought that these APOBEC3s would be less likely to act on
host genomic DNA and lead to oncogenic transformation. Starting in 2012, however, large-scale
sequencing studies performed on hundreds of cancer genomes revealed evidence suggestive of
AID/APOBEC activity on human genomic DNA (Alexandrov et al., 2013; Nik-Zainal et al.,
2012). In short, the authors of these studies algorithmically classified nearly two dozen
“mutational signatures” across a variety of cancer types based on types/patterns of base changes,
local sequence context of the mutations, strand specificity, and other factors. The authors
preliminarily ascribed two of these signatures (signatures 2 and 13 from Alexandrov, Nature
2013) to AID/APOBECs based on empirical knowledge of two known features associated with
the targeting mechanism of these enzymes. First, the mutations occurred in clusters (coined
“kataegis,” Greek for thunderstorm), likely indicative of availability of exposed ssDNA substrate
from breaks/repair processes, and secondly, these kataegis events occurred specifically at
cytosine bases with a favored 5’-TC sequence context, a property whose molecular basis is
3

explored in the next section. Notably, this mutational signature, coupled to expression analysis in
cancer cells, has implicated human APOBEC3A and APOBEC3B as the leading candidates
associated with oncogenic APOBEC3 activity (Roberts et al., 2012; Burns, Lackey et al., 2013;
Burns, Temiz et al., 2013; Taylor et al., 2013; Roberts et al., 2013; Nik-Zainal et al., 2014;
Henderson and Fenton, 2015).
As alluded to above, each AID/APOBEC enzyme exhibits a local sequence context
preference for optimal activity. This property derives from specific molecular interactions
between each AID/APOBEC enzyme and its ssDNA substrate, mostly at the positions directly
flanking the target cytosine. Extensive biochemical work has demonstrated that the protein
residues that make up this binding interface can be localized to a single loop in the enzyme
family, known as the “hotspot recognition loop” (HRL). The specific loop of each family member
is a major determinant of its distinctive sequence preferences, and one study demonstrated that
“grafting” the HRL from one enzyme to another can successfully change the local sequence
preference of the recipient enzyme (Kohli et al., 2009). Another study identified one specific
residue (D317) in APOBEC3G that when singly point-mutated to a tyrosine (the cognate base in
APOBEC3A) produces a 5’-CC to 5’-TC sequence preference change, recapitulating the effect of
grafting the entire loop (Rathore et al., 2013).
Although many apo-structures of various AID/APOBEC family members have been
determined, the precise molecular mechanism of these critical interactions between the protein
HRL and the DNA substrate eluded researchers for years. In 2017, the first high-resolution
structure of an AID/APOBEC family member in complex with its nucleic acid substrate was
solved for A3A and a short piece of ssDNA (Shi et al., 2017). Interestingly, the ssDNA was
determined to bind in a ‘U’-shaped conformation, with the target cytosine at the bottom of the ‘U’
and only immediately-flanking bases making direct, sequence-specific contacts with the protein.
Shi and colleagues also crystallized a mutant form of a related family member, APOBEC3B
(denoted A3Bctd*; Shi et al., 2017 and Schutsky, Hostetler et al., 2017) which was found to bind
4

ssDNA via a similar mechanism; however, the residues that make direct contacts with the DNA
were the few that were mutated and therefore not native to A3B. Although the generalizability of
this phenomenon remains unclear, the U-shaped conformation could explain why the empiricallydetermined sequence preferences rely most strongly on the immediately-flanking bases, and less
strongly even on bases two positions removed from the target cytosine.
The ssDNA-bound structure of A3A not only points to non-specific protein interactions
with the ssDNA phosphate backbone, but also to why specific residues are most preferred at sites
immediately flanking the target cytosine. Notably, biochemical and sequencing analyses
determined A3A’s sequence preference to be 5’-TTCA-3’, with the strongest influencer of
activity being the 5’ thymine directly upstream of the target cytosine (Logue et al., 2014; Shi et
al., 2017). In the crystal structure of the complex, the cyclic NH at the 3-position and the
exocyclic keto group at the 4-position of the 5’ thymine made specific hydrogen bonding
interactions with the carboxylic acid side chain of D131 of the HRL, and the base as a whole is
stably “flipped out” of the loop via engagement with a hydrophobic binding pocket comprised of
W98 and Y130/Y132 of the HRL.
As noted earlier, in the context of the oncogenic signatures, mutations ascribed to
AID/APOBECs were found predominantly in 5’-TC contexts, leading to the hypothesis that A3A
or A3B (which contains the same HRL and therefore similar local sequence preferences) could
contribute to mutagenesis. In Chapter 2 of this thesis work, I provide robust biochemical
characterization of A3A, including specific quantification of its local sequence preferences for
deamination. In Chapter 3 of this thesis work, I consider the impact of A3A’s sequence
preference on the development of APOBEC-Coupled Epigenetic Sequencing (ACE-Seq)
throughout the optimization. Other approaches to overcome the sequence specificity challenge for
biotechnological development will be discussed in Chapter 4 (4.3).
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1.1.2.2 Epigenetic regulation via deamination-coupled demethylation
For decades, scientists have understood and appreciated how cytosine bases in
mammalian genomes, predominantly in CpG dinucleotide contexts, can be methylated at the 5position by the action of DNA methyltransferase (DNMT) enzymes. Extensive exploration into
the role of 5-methylcytosine (mC) revealed a predominant role for mC in gene silencing and a
crucial function in the regulation of gene expression, especially during embryonic development
and in the context of imprinted genes. The methylation status of a CpG dinucleotide—either
methylated or unmethylated—provides an additional “bit” of information that is layered on top of
the primary sequence of the genome. This view implies that, just as base-pairing in the genome
permits information to be transduced from one strand to the next upon replication, so too must the
information encoded by CpGs. Indeed, the DNMT enzymes can fulfill just such as role. While
DNMT3A/3B are known as de novo methyltransferases, DNMT1 is a maintenance enzyme that
shows a strong preference for acting on hemi-methylated CpG dinucleotides generated after the
genome is replicated in order to generate symmetrically-methylated CpGs.
While the mechanism by which mC bases are introduced is well understood, the process
by which mC bases can be erased from the genome remains elusive. Through a process of DNA
“demethylation,” genes that may have been silenced by mC become reactivated. In one
established pathway known as “passive” demethylation, the removal of mC bases occurs simply
by excluding DNMT1 from acting on newly replicated DNA. Genome replication in the absence
of DNMT1 passively dilutes mC levels with each cycle of replication. However, many instances
exist in which where demethylation occurs in the absence of DNA replication, such as the rapid
demethylation of the paternal genome that has been observed to occur immediately following
fertilization (Mayer et al., 2000; Oswald et al., 2000). The simplest pathway for such “active”
DNA demethylation would involve direct enzyme-catalyzed removal of the methyl group from
the 5-position; however, the absence of any known direct demethylase enzyme coupled with the
chemical difficulty of cleaving a carbon-carbon bond makes a one step “active” demethylation
6

pathway less likely. An elegant pathway exists in plants like Arabidopsis thaliana in which a mC
DNA glycosylase known as DEMETER directly excises the entire mC base from the genome,
leaving an abasic site which can then be filled with an unmodified cytosine via base-excision
repair pathways (Gehring et al., 2006; Morales-Ruiz et al., 2006). However, no known mC DNA
glycosylases or DEMETER homologues have been identified in animals.
Shortly after the discovery of AID/APOBEC enzymes, several groups have suggested the
that enzymatic DNA cytosine deamination could contribute to active DNA demethylation. In the
simplest model invoking AID/APOBECs, deamination of mC would lead to generation of a
thymine base across from an original guanine (T:G mismatch). Such a mismatch would trigger
recognition and repair by Thymine DNA Glycosylase (TDG), restoring the unmodified C:G pair
as part of the base-excision repair pathway. This model is supported by a report of AID and
APOBEC1 mC deamination activity in vitro and in E. coli cells as well as evidence of AID and
APOBEC1 co-expressing with critical pluripotency genes (Morgan et al., 2004). In zebrafish,
injected methylated DNAs were observed to undergo demethylation, which was compromised
when AID and/or MBD4 (a thymine DNA glycosylase analog) were knocked down;
overexpression of these factors also led to demethylation of the bulk genome (Rai et al., 2008). In
a non-physiological situation, heterokaryon fusions of mouse embryonic stem cells with human
fibroblasts resulted in genomic demethylation and expression of OCT4 and NANOG pluripotency
factors; this phenotype was prevented in the case of siRNA-mediated knockdown of AID
(Bhutani et al., 2010). Additional evidence in support of AID-dependent demethylation of mC in
demethylation came from the later demonstration that deletion of TDG is embryonic lethal in
mice and results in epigenetic abnormalities, although alternative explanations for such
observations have been entertained (Cortellino et al., 2011).
The models invoking AID/APOBEC activity became more complicated starting in 2009
with the discovery of another cytosine modification, 5-hydroxymethylcytosine (hmC), which
arises via the oxidation of the methyl group of mC by the Ten-Eleven Translocation (TET) family
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of dioxygenases (Kriaucionis and Heintz, 2009; Tahiliani et al., 2009). Even though little was
understood about the function of hmC in genomic DNA, multiple groups extrapolated their
deamination-dependent demethylation hypotheses to include this new base: if hmC could be
deaminated by AID/APOBECs to form hydroxymethyluracil (hmU), this mispair could be
recognized and similarly replaced by unmodified cytosine. Support for this model emerged when
TDG, Single-stranded Monofunctional Uracil-DNA Glycosylase (SMUG), and methyl CpGbinding domain protein 4 glycosylase (MBD4) were found to recognize and excise hmU:G
mismatches (Boorstein et al., 2001; Cortellino et al., 2011; Hashimoto et al., 2012). Another
study showed that overexpression of AID and other family members in HEK293 cells caused a
decrease both in Tet1-induced hmC formation in genomic DNA and in transfected hmCcontaining DNA (Guo et al., 2011). Even a few years later in 2011 when further Tet-generated
oxidation products of mC (5-formylcytosine (fC) and 5-carboxylcytosine (caC)) were detected in
genomic DNA (Ito et al., 2011), many groups continued to hypothesize that mispairing via
deamination of any of these modified cytosines in the “extended epigenome” could be recognized
and repaired by various members of the base-excision repair pathway (Xue et al., 2016).
Despite the accumulation of evidence suggesting a role for AID/APOBECs in
demethylation, several caveats also exist. For one, because AID/APOBECs exclusively act on
ssDNA, the widespread and rapid deamination of predominantly double-stranded genomic DNA
presents an enzymatic problem of substrate accessibility. Following the discovery of fC and caC,
it was empirically determined that TDG, previously thought to act only on T:G mismatches, also
exhibited efficient glycosylase activity directly on fC and caC (Maiti and Drohat, 2011)1.

1

Intriguingly, neither of these bases in DNA would be recognized as a mismatch, as Watson-Crick base-pairing is
maintained with the opposite guanine. Instead, it is thought that the electron-withdrawing properties of the formyl
group and the resonance of the fC base stabilizes the leaving group, which allows more efficient excision by TDG
(Pidugu et al., 2016; Drohat and Coey, 2016). Alternatively, the carboxylate group is electron-donating and is an
inefficient leaving group under physiological conditions; TDG is therefore thought perform acid catalysis by flipping
out the base and protonating it to render it neutral and provide a better leaving group (Maiti et al., 2013; Drohat and
Coey, 2016).
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By definition, the deamination-dependent demethylation pathway described above
invokes deamination of modified cytosines by AID/APOBEC enzymes; however the biochemical
feasibility of this putative pathway had yet to be demonstrated. In 2012, our laboratory quantified
the activity of human AID, mouse APOBEC1, and mouse APOBEC3 on cytosine and its various
analogs. Compared to the activity of these enzymes on unmodified cytosine, their mC activity
was reduced about ten-fold. Moreover, none of these enzymes demonstrated detectable activity
for hmC (Nabel, Jia et al., 2012). In addition, the activity of AID/APOBECs on the newlydiscovered fC and caC has never been previously assessed. In Chapter 2 of this thesis work, I will
quantify APOBEC3A activity on all modified cytosines, including fC and caC, and provide
rationale for its substrate preference for cytosine modification states. In Chapter 3 of this thesis
work, I will exploit these substrate preferences in order to develop an APOBEC-based sequencing
technology to specifically and precisely localize hmC in the genome, which will provide critical
insight into its function in a variety of cell/tissue types, embryonic timepoints, and disease states.

1.1.3

Biotechnological applications of AID/APOBECs in gene editing
The mutagenic nature of the reaction catalyzed by AID/APOBEC enzymes has drawn

considerable attention recently given the advent of elegant gene editing technologies, like
CRISPR/Cas. In its most widely applied form, a Cas nuclease is loaded with a guide RNA that
will directly base pair to the genomic target of interest. After binding, the Cas nuclease will
cleave the DNA backbone, generating a double-stranded break that will be repaired either through
non-homologous end joining, thereby generating indels and disrupting the gene of interest, or
through homology-directed repair with an exogenously-supplied donor DNA strand containing a
sequence of interest.
Due to the unpredictable nature of repair following Cas9 cleavage, many groups have
sought to utilize non-nuclease editing enzymes that could cause specific mutations without
cleaving the DNA backbone and initiating repair pathways (reviewed in DeNizio et al., 2018). An
9

important advance in genome editing approaches came with the consideration that
AID/APOBECs could be exploited in such systems, as they lack nuclease activity and can
generate CT point mutations (or GA mutations in the opposite strand) via unrepaired
deamination and subsequent replication. Initial efforts to this end employed an APOBEC1
enzyme fused to a catalytically dead Cas9 mutant (dCas), the latter of which targets the correct
locus and unwinds target DNA without cleavage activity (Komor et al., 2016). Importantly, this
construct also fused UGI, a proteinaceous inhibitor of Uracil DNA Glycosylase (UDG), to
prevent in vivo repair of the CU deamination event, allowing for more efficient editing. AID
homologs have also been used successfully as “base editors” in place of APOBEC1, again fused
to either UGI or other effector domains (Nishida et al., 2016; Zong et al., 2017).
Ongoing efforts to refine the utilization of natural base editors for biotechnological
applications include achieving higher editing efficiencies and limiting off-target effects. To this
end, many groups have applied known structural and biochemical insight into AID/APOBECs
(discussed in 1.1.2) to tune and optimize their engineered editing systems. One group,
recognizing the ability of AID/APOBECs to modulate targeting via their specific HRL, found that
mutating R126 and R132 in and around the HRL of APOBEC1 limited the scope of editing to a
narrower window than the WT enzyme while maintaining similar editing efficiencies at those
targeted sites (Kim et al., 2017). Beyond AID/APOBECs, many groups have employed an
inactivated Cas protein fusion strategy with other DNA-modifying enzymes, like DNMTs and
TETs, for use in studying the specific effects of modifications at a single base in the genome
(Amabile et al., 2016; Vojta et al., 2016; X. S. Liu et al., 2016; Morita et al., 2016; McDonald et
al., 2016; Y. H. Huang et al., 2017; Stepper et al., 2017). As a potential complementary approach,
removal of those specific modification by a targeted AID/APOBEC fusion could also reveal the
function of modified cytosines of interest in the genome.
While non-canonical functions of and potential biotechnological uses for AID/APOBECs
have garnered much interest over the last decade, a recurring limitation is the lack of precise,
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molecular understanding of AID/APOBEC-catalyzed deamination activity on non-canonical
substrates. In Chapter 2 of this thesis work, I will provide a rigorous biochemical framework for
understanding the activity of the most catalytically-active family member in vitro, APOBEC3A.
Specifically, I will focus on the activity of APOBEC3A on modified cytosines that comprise the
extended epigenome, which will provide crucial insight into not only how these enzymes act in
vivo, but also how they could be exploited to create tools for further epigenetic understanding.

1.2

Function and localization of cytosine modifications in the extended epigenome

1.2.1

The dynamic nature of the mammalian genome
Recent work has transformed how biologists view the mammalian genome. Traditionally,

RNA and proteins were thought of as the “dynamic” molecules of biology: Their short-lived and
non-heritable nature allows for post-transcriptional/post-translational modifications to precisely
regulate cellular responses to stress or environmental stimuli on a short time scale. In contrast,
DNA had been confined to a “stable” paradigm: Faithful replication of DNA demands
sequestration in the nucleus and protection from any sort of modification, damage, or editing so
that it can be and inherited by daughter cells for generations without incurring damaging
mutations. While all of these qualifications for genomic DNA are usually satisfied, adaptability of
the genome is being recognized as essential for a number of cellular processes linked to survival.
For example, as discussed in Section 1.1.1, AID specifically hypermutates immunoglobulin loci
in B cells to promote antibody affinity maturation, thereby responding rapidly and broadly to
new, foreign threats. While this process opens the door to potential errors, it is critical for
response to infection. This balancing act between stability and adaptability is necessary to exist in
a world full of ever-evolving threats to survival of a species.
Beyond deamination, which can lead to disastrous base changes if not properly regulated
or repaired, other enzymatic processes also regulate the plasticity and temporal dynamics of the
genome. All together, these processes make up the field of “epigenetics,” defined as any
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regulatory mechanisms that exist “on top of” or “in addition to” strict base/nucleotide identity and
patterning. Epigenetic mechanisms broadly include post-translational modifications to histone
proteins (which scaffold compaction of DNA into nucleosomes and further into densely-packed
chromatin), transcriptional and post-transcriptional regulation via non-coding RNAs, and direct
modifications to DNA bases that do not perturb the identity of the DNA base or significantly
impact Watson-Crick base. This section and thesis work will focus on this lattermost epigenetic
regulatory mechanism – direct DNA modification.

1.2.2

Cytosine modifications – demethylation intermediates or independent bases?
Beyond the original genetic code made up of adenine (A), cytosine (C), thymine (T), and

guanine (G), the four recently-discovered modified versions of cytosine have expanded our
genomic repertoire to eight DNA bases. Stemming from the paradigm of DNA as “stable,” the
purposes of ox-mC bases (hmC, fC, and caC) have remained controversial for the last decade.
Specifically, the field has questioned whether these ox-mC bases are simply byproducts of a
necessary pathway for reversal of methylation-mediated gene silencing or whether they each play
independent genetic roles as stable bases. As potential demethylation intermediates, ox-mCs
generated by the Tet enzyme family would be removed by TDG/BER and replaced with
unmodified cytosine. In support of this idea, all ox-mCs are detected at levels below C and mC
across the genome, although hmC can, in some cell types, approach levels similar to mC
(Kriaucionis and Heintz, 2009; Lister et al., 2013). Notably, fC and caC are particularly rare,
making up approximately 1 in 105-6 cytosines in most cell types (Ito et al., 2011; Pfaffeneder et
al., 2011; Bachman et al., 2015). Further, depletion of TDG increases levels of fC and caC (L.
Shen et al., 2013; Song et al., 2013; Wu et al., 2014), providing biological validation that TDG
removal of these bases is of physiological import. In a complementary experiment,
overexpression of TET and TDG was shown to drastically reduced fC and caC to nondetectable
levels by LC-MS/MS (Nabel, Jia et al., 2012).
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In addition to their roles in active DNA demethylation, hmC, fC, and caC have also been
interrogated for possible independent, non-redundant roles in the regulation of gene expression.
One avenue for arguing independent function comes from the perspective of stability – are these
bases constantly being generated and recycled, or can they resist TDG excision and remain longlived? To this end, many groups have used mass spectrometry techniques to track not only overall
abundance, but also cell-type-specific and site-specific levels of hmC, fC, and caC. While some
groups have reported long-lived hmC and fC marks (Bachman et al., 2014; Bachman et al., 2015;
Iurlaro et al., 2016) or semi-permanent marks (Su et al., 2016), other groups noted age-related
declines in levels, notably of fC, suggesting minimal independent functions apart from
intermediates in demethylation (Wagner et al., 2015). Intriguingly, many groups also mapped
hmC and fC to distinct genomic features and/or specific sites, also suggesting that they could be
playing independent roles (Wu and Zhang, 2015). Finally, reports of specific reader proteins for
hmC, fC, and caC (Iurlaro et al., 2013; Spruijt et al., 2013) suggest ox-mC bases may interface
with different pathways like DNA repair and transcription regulation, while other studies observe
direct changes in DNA structure/base-pairing (Raiber et al., 2015; Szulik et al., 2015) or rates of
RNA Polymerase II elongation in DNA strands with fC or caC bases (Kellinger et al., 2012;
Wang et al., 2015). Given all of this evidence, it is this author’s assessment that while fC and caC
are necessary intermediates in active DNA demethylation, they likely also have independent
functions that require further study. In the case of hmC, this statement is far less controversial,
mostly stemming from the fact that hmC is significantly more prevalent than fC and caC in all
cell/tissue types studied, even reaching up to 40% of modified cytosine levels overall in Purkinje
neurons (Kriaucionis and Heintz, 2009).
Due to high levels of hmC, especially in brain tissue, empirical studies for hmC are more
straightforward than those for fC and caC and have allowed preliminary characterization of a
functional role. On the whole, hmC is thought to be an “activating” mark, generally negating the
silencing effects of mC, and it tends to be enriched in gene bodies, at intron-exon boundaries, and
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in enhancer regions (reviewed in Moen et al., 2015). One question of interest in neuroscience is
what role cytosine modifications and their reader proteins play in gene expression and disease.
Specifically, mutations in MeCP2—one of the most well-studied readers of mC in the brain—
have been determined as the direct cause of Rett syndrome, an X-linked disorder that leads to
severe neurological phenotypes in females (Amir et al., 1999). MeCP2 has been shown to bind
tightly to mC-rich regions where mCs are in CpG dinucleotide contexts (i.e. mCpG) and in nonCpG contexts (i.e. mCpH), the latter of which is a mark almost exclusively limited to the brain.
Interestingly, when tested in gel shift assays with short pieces of DNA containing an mCpG,
mCpH, hmCpG, or hmCpH, MeCP2 was found to bind to all of these marks except hmCpG
(Gabel et al., 2015). Therefore, the brain-specific role of mC to hmC oxidation in CpG contexts
could be to inhibit binding of MeCP2 and alleviate gene repression. However, the physiological
consequence of MeCP2’s biochemical/biophysical association with hmCpH is unclear, as hmCpH
levels in the brain have generally been reported to be very low (<2%) (Lister et al., 2013).

1.2.3

Methods for localizing ox-mCs at single base resolution
Initial efforts to characterize the function of ox-mC bases typically involves determining

their prevalence in vivo in diverse cell types. To this end, the first methods to identify these bases
in DNA came from antibody pulldown-based experiments using antibodies specifically raised
towards one of the ox-mCs. For example, one could qualitatively detect an ox-mC by applying
genomic DNA to a membrane, binding an ox-mC antibody, and then visualizing with a variety of
reagents. For a more quantitative approach, one can assay ox-mC prevalence by digesting
genomic DNA to nucleosides, running the nucleosides through an LC-MS/MS protocol, and
comparing to known standards. While providing much more sensitive and quantitative insight
into ox-mC levels, neither this method nor the antibody-based assay described above provides
any sort of information about the location of these bases, but solely the overall amount in the
given sample.
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To localize these ox-mCs in the genome, immunoprecipitation using the antibodies
described above has been successfully coupled to downstream microarrays or sequencing
technologies to broadly localize regions of high density modifications (reviewed in Thomson et
al., 2013). One drawback of affinity-based approaches is that there can be nonspecific pulldown
resulting in false positive detection of hmC. Also, some iterations of these techniques are thought
to require high-density hmC modifications, which would limit the detection of areas of lowdensity hmCs. A more-successful modification of this approach relies on the conversion of hmC
upon bisulfite treatment to cytosine 5-methylenesulfonate (CMS), which can be successfully and
more specifically pulled down with an antibody specific to the CMS base (CMS-IP; Y. Huang et
al., 2012). Other pulldown-based methods like GLIB-Seq (Pastor et al., 2012) and hmC-Seal-Seq
(Han et al., 2016) have also been employed; however, all of these methods are limited in the
sense that they can only provide approximate genomic areas of localization and not baseresolution information.
Most technologies aimed at localizing specific ox-mCs at base resolution in the genome
build off the precedent of bisulfite sequencing (BS-Seq), which is the “gold standard” for the
identification of mC at single base resolution in genomic DNA. In BS-Seq, genomic DNA is
chemically treated with bisulfite, which selectively sulfonates unmodified cytosine at the 6position of the base under acidic conditions and elevated temperatures. This sulfonation event
then allows for spontaneous hydrolytic deamination of the cytosine, after which the reaction is
moved to alkaline pH which promotes desulfonation, generating uracil as the final product.
Methylated cytosines, however, are largely resistant to the initial sulfonation step, and, do not
readily deaminate under the same conditions used for unmodified cytosine. Therefore, in order to
distinguish between C and mC by sequencing, a sample can be treated with bisulfite, sequenced,
and compared to an untreated reference sample; all originally unmodified Cs read out as Ts after
sequencing the bisulfite-treated sample whereas all mCs should read out as Cs.
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The readout of bisulfite sequencing became more complicated following the discovery of
the ox-mC bases. Despite their modifications, while fC and caC were found to readily sulfonate
and deaminate upon bisulfite treatment, whereas hmC was found to form a bulky, sulfonated
adduct known as cytosine 5-methylenesulfonate (CMS) that resists hydrolytic deamination (Y.
Huang et al., 2010). Therefore, in a given genomic DNA sample, C, fC, and caC would all read
out as Ts post-bisulfite treatment, whereas mCs and hmCs would read out as Cs. To partially
resolve this dilemma, specific base-resolution technologies have been successfully developed for
fC and caC, again based on their ability to deaminate with bisulfite treatment (Wu et al., 2014;
Neri et al., 2015; Wu et al., 2016). Data from standard bisulfite sequencing is still commonly
interpreted exclusively as mC to this day regardless of the complications arising from the oxmCs, generally because most cell/tissue types contain the ox-mCs at relatively lower levels than
those of mC.
As described in Section 1.2.2, this assumption negligible ox-mC levels cannot be made in
the context of neuronal cells or whole brain tissue, as hmC levels nearly approach those of mC.
Therefore, new sequencing technologies were required to distinguish between these two bases at
single base resolution. The first methodology to emerge that distinguishes between mC and hmC
is Tet-assisted bisulfite sequencing (TAB-Seq), and it remains the most commonly utilized to date
(Yu, Hon, Szulwach, Song, Zhang et al., 2012; Yu, Hon, Szulwach, Song, Jin et al., 2012).
Building on the previously-established bisulfite sequencing platform, TAB-Seq specifically
changes the reactivity of mC to bisulfite by using Tet enzymes to oxidize mC up to either fC or
caC, either of which is deaminated via bisulfite treatment. Contrarily, hmC is protected from Tetmediated oxidation via addition of a glucose moiety to its 5-position hydroxymethyl group using
beta-glucosyltransferase (βGT) from T4 phage and uridine-diphosphate glucose (UDP-Glc) as a
glucose donor. Another analogous technique which also modulates bisulfite reactivity of the
modified ox-mC bases is oxidative bisulfite sequencing (oxBS-Seq), in which hmC is specifically
oxidized to fC by treatment with potassium perruthenate. Then, upon bisulfite treatment, mC
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bases are the only ones not deaminated; hmC positions can then be ascertained via subtraction of
this signal from the signal from the signal from standard bisulfite treatment, which provides
combined mC + hmC readout.
The main caveat of all of these methods is the reliance on bisulfite treatment. To achieve
robust C, fC, and caC deamination, DNA in the bisulfite reaction is cycled between 95 ºC and 60
ºC for up to 16 hours in acidic conditions before shifting the pH of the reaction to the highly
alkaline range for desulfonation. These conditions are particularly damaging to DNA, mostly
through generation of abasic sites and global DNA fragmentation, resulting in up to 99.9% loss of
input DNA (Tanaka and Okamoto, 2007). Therefore, the use of bisulfite makes generating highcomplexity sequencing libraries of mammalian genomes with lower inputs of DNA challenging,
especially for populations that are small or transient, like from early embryonic tissue at certain
post-fertilization timepoints, or even single cell or cell-free DNA analysis.
Many groups have recently begun proposing, validating, and optimizing methodologies
that could maintain the same levels of accuracy and precision of the bisulfite-based methods
while using less-destructive treatments to enable the analysis of samples with limited DNA input.
For example, a single-cell-proficient technology for fC sequencing has been developed that
selectively labels fC with a malononitrile chemical group, which then allows for increased rates
of CT conversion (Zhu et al., 2017). A few proposed approaches for hmC sequencing utilize
restriction enzymes that selectively cleave downstream of hmC (Z. Sun et al., 2013; Z. Sun et al.,
2015); however, data from these experiments generally show high false-positive rates, leading to
the hypothesis that these methods overcall hmCs. Overall, none of these bisulfite-free methods
have yet to be widely adopted by the epigenetics community, so their statistical accuracy has yet
to be validated. In Chapter 3 of this thesis work, I introduce a novel bisulfite-free sequencing
technology called APOBEC-Coupled Epigenetic Sequencing (ACE-Seq) for base-resolution
localization of genomic hmC with low DNA input.
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1.3

Thesis objectives
The aim of this thesis is to explore the biochemical underpinnings of the many proposed,

non-canonical roles of AID/APOBECs beyond their immunologic functions while also
demonstrating a powerful biotechnological application of these family members in localizing
modified cytosine bases in the genome.
In Chapter 2, I describe a novel restriction enzyme-based system I developed in which
the activity of APOBEC3A on all known modified cytosines can be sensitively assayed and
directly compared between substrates. Using this assay, I determine the catalytic competence of
APOBEC3A on both natural and unnatural cytosine substrates using multiple-turnover kinetics. I
report the first kcat (and in some cases KM) values for APOBEC3A on all known cytosines and
conclude that while APOBEC3A is catalytically competent for both C and mC (with only a ~4fold drop in activity from C to mC), there is a ~5000-fold decrease in activity for hmC/fC and no
detectable product formation for caC. These biochemical observations are corroborated by the
now-available structure of APOBEC3A in complex with its preferred ssDNA substrate. These
biochemical conclusions also imply that the proposed oxidation-deamination coupled pathways to
active DNA demethylation are highly disfavored and unlikely to occur in vivo to a significant
extent.
In Chapter 3, I describe a novel epigenetic sequencing method called APOBEC-Coupled
Epigenetic Sequencing (ACE-Seq) that exploits our biochemical understanding of APOBEC3A to
discriminate between cytosine modification states in genomic DNA and allow for base-resolution
localization of hmC with limited DNA input. I describe each of the challenges faced in employing
APOBEC-mediated deamination in this method and the optimization/validation experiments
performed to overcome these challenges. After demonstrating the initial validation of this method
on genomic phage DNA with homogeneous modifications, I highlight the use of this technology
on mammalian DNA from mouse embryonic stem cells (mESCs) and excitatory neurons from
mouse cortex. The strength of the method is validated through calculation of an empirical false
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discovery rate (using Tet triple knockout (TKO) ESCs as a control) and correlation with TABSeq data on highly similar cell populations. Additionally, I demonstrate the utility of this method
for sequencing low input DNA and also for generation of long amplicons, both of which are
limitations of previously “gold standard” technologies.
Finally, in Chapter 4, I describe ongoing work aimed at elucidating the functions of
AID/APOBECs in various physiological and pathological processes, as well as continuing efforts
to further develop ACE-Seq for use in single-cell sequencing platforms and for sequencing other
modified cytosine bases.
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CHAPTER 2: Activity of APOBEC3A on the Extended Epigenome

This chapter has been adapted from the following manuscript:
Schutsky E.K., Nabel C.S., Davis A.K.F, DeNizio J.E., Kohli R.M. (2017). APOBEC3A
efficiently deaminates methylated, but not TET-oxidized, cytosine bases in DNA.
Nucleic Acids Research 45(13):7655-7665.2

2.1

Abstract
AID/APOBEC family enzymes are best known for deaminating cytosine bases to uracil

in single-stranded DNA, with characteristic sequence preferences that can produce mutational
signatures in targets such as retroviral and cancer cell genomes. These deaminases have also been
proposed to function in DNA demethylation via deamination of either 5-methylcytosine (mC) or
TET-oxidized mC bases (ox-mCs), which include 5-hydroxymethylcytosine, 5-formylcytosine,
and 5-carboxylcytosine. One specific family member, APOBEC3A (A3A), has been shown to
readily deaminate mC, raising the prospect of broader activity on ox-mCs. To investigate this
claim, we developed a novel assay that allows for parallel profiling of activity on all modified
cytosines. Our steady-state kinetic analysis reveals that A3A discriminates against all ox-mCs by
>3700-fold, arguing that ox-mC deamination does not contribute substantially to demethylation.
A3A is, by contrast, highly proficient at C/mC deamination. Under conditions of excess enzyme,
C/mC bases can be deaminated to completion in long DNA segments, regardless of sequence
context. Interestingly, under limiting A3A, the sequence preferences observed with targeting
unmodified cytosine are further exaggerated when deaminating mC. Our study informs how

2

I, as the primary author, performed most of the experiments in this section. I, along with C.S.N. and R.M.K.
conceived of the experiments. J.E.D. assisting in design of the long single-stranded substrate utilized in the sequence
preference profiles (Figure 3). A.K.F.D. optimized a primer-extension method for generating the necessary
formyluracil and carboxyluracil controls for the kinetic characterization (Fig XX, Supp Fig XX).
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methylation, oxidation, and deamination can interplay in the genome and suggests A3A’s
potential utility as a biotechnological tool to discriminate between cytosine modification states.

2.2

Introduction
Members of the AID/APOBEC family of cytosine deaminases are nucleic acid editing

enzymes that function in both adaptive and innate immune contexts (Siriwardena et al., 2016).
Activation-induced deaminase (AID), a founding member of the family, targets host genome
immunoglobulin loci to initiate antibody somatic hypermutation and class switching (Muramatsu
et al., 2000). The APOBEC3 subfamily targets foreign genomes, including retroviruses and
retrotransposons, rendering them unable to replicate or targeting them for degradation (Harris et
al., 2003). Each deaminase family member has distinctive sequence preferences and therefore
leaves a different mutational signature (Conticello et al., 2007). Nonetheless, the canonical
reaction for AID and the APOBEC3 enzymes in these settings is the same: deamination of the 4position of the cytosine base in single-stranded DNA (ssDNA), forming uracil.
Aside from their established roles in immunity, several other functions have been
proposed for these DNA deaminases, mainly involving their activities on noncanonical substrates
(Figure 2-1). Several family members have been shown to deaminate 5-methylcytosine (mC), a
common gene silencing mark, although activity on mC is 5- to 15-fold less than on unmodified
cytosine (Abdouni et al., 2013; Morgan et al., 2004; Nabel, Jia et al., 2012; Rangam et al., 2012).
Human APOBEC3A (A3A) has garnered particular attention as it can more efficiently deaminate
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mC, with rates only slightly reduced relative to unmodified cytosine in both biochemical and
cellular assays (Carpenter et al., 2012; Suspene et al., 2013; Wijesinghe and Bhagwat, 2012). This

Figure 2-1. Physiological and pathological roles of AID/APOBEC enzymes.
In the genome, cytosine can be found in various forms: unmodified (C), methylated (mC), or oxidized
mC bases (hmC, fC, and caC). The canonical function of AID/APOBECs in both innate and adaptive
immunity is deamination of unmodified cytosine to uracil (green boxes). Mutational signatures in cancer
have implicated AID/APOBEC activity on the human genome, on unmodified cytosine or possibly on
mC (red boxes). Alternative physiological roles for APOBECs have also been proposed (blue boxes),
including in active DNA demethylation. These proposed pathways involve deamination of modified
cytosine bases to their corresponding uracil analogs, followed by base excision repair to revert the original
base to an unmodified cytosine.

enhanced mC deamination activity by A3A has been proposed to function in restriction of foreign
methylated DNA (Stenglein et al., 2010); however, whether this efficient activity on mC extends
to cytosines with even bulkier modifications has yet to be explored.
This question is particularly relevant as AID/APOBEC deaminases have been proposed
to play a role in active DNA demethylation (Mayer et al., 2000; Oswald et al., 2000). Currently,
the most widely accepted view of DNA demethylation first involves oxidation of mC by teneleven translocation (TET) family enzymes, producing 5-hydroxymethylcytosine (hmC), 5formylcytosine (fC), and 5-carboxylcytosine (caC) via stepwise oxidation (Ito et al., 2011; He et
al., 2011). The latter two oxidized mC (ox-mC) bases can be removed by thymine DNA

22

glycosylase (TDG), a base excision repair (BER) enzyme, and resultant repair provides a feasible
complete cycle for DNA demethylation (He et al., 2011; Ito et al., 2011; Kohli and Zhang, 2013;
Maiti and Drohat, 2011). However, since TDG and other DNA glycosylases have also been
shown to excise modified uracils, an alternative, accessory model for demethylation exists
involving AID/APOBEC deamination. In this model, the modified cytosine is deaminated to
generate a genomic mismatch, which can be repaired to unmodified cytosine by BER (Bhutani et
al., 2011; Drohat and Coey, 2016; Nabel, Manning et al., 2012). Pathways invoking mC
deamination (Bhutani et al., 2010; Cortellino et al., 2011; Morgan et al., 2004; Rai et al., 2008),
hmC deamination (Cortellino et al., 2011; Guo et al., 2011; Hashimoto et al., 2012), or caC
deamination (Xue et al., 2016) have all been proposed as possible contributors to DNA
demethylation (Figure 2-1). Among ox-mCs, only deamination of hmC has been directly
examined with select AID/APOBEC family members. Prior biochemical work showed that
human AID, mouse APOBEC1, and mouse APOBEC3 all discriminate against this bulky
modification (Nabel, Jia et al., 2012; Rangam et al., 2012): deamination of hmC was at least 100fold slower than unmodified C but could not be further quantified due to the detection limit.
Importantly, no study has yet tested AID/APOBEC activity on fC and caC. 5hydroxymethyluracil (hmU) and 5-formyluracil (fU) have been detected in genomes (Gackowski
et al., 2015; Globisch et al., 2010; Pfaffeneder et al., 2014; Samson-Thibault et al., 2012);
however, whether these bases are derived from enzymatic deamination, oxidative damage or
other processes such as TET-mediated oxidation of thymidine rather than mC remains unclear
(Pfaffeneder et al., 2014; Samson-Thibault et al., 2012). Therefore, though often cited as
plausible, demethylation involving oxidation and enzymatic deamination in concert has yet to be
validated biochemically.
Recent work has also called attention to the pathological roles of AID/APOBEC
enzymes, as many cancer genomes were found to harbor clusters of strand-coordinated mutations
that were predominantly C-to-T transitions in a 5’-TC sequence context (Alexandrov et al., 2013;
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Burns, Lackey et al., 2013; Nik-Zainal et al., 2012; Roberts et al., 2013). This phenomenon,
known as kataegis, is thought to arise from enzymatic deamination in areas of exposed singlestranded DNA (Lada et al., 2012; Taylor et al., 2013). The 5’-TC sequence preference implicated
A3A and its closely-related family member APOBEC3B (A3B) in these clustered mutations
(Burns, Lackey et al., 2013; Logue et al., 2014; Nik-Zainal et al., 2014; Vartanian et al., 2008).
Although the 5’-TC sequence preference of A3A and A3B is well established, the impact of
methylation status on these deamination preferences has not been previously investigated. This
question is important because the interplay between sequence context dependence and C/mC
deamination activity could aid in deciphering these deaminases’ mutational footprint on cancer
genomes.
In this study, we devised and applied a novel restriction enzyme-coupled assay that
allows for parallel determination of the steady-state kinetic parameters for A3A on all epigenetic
cytosine modifications. Our results reveal that, despite its efficient activity on mC, A3A potently
discriminates against hmC at rates that can now be quantified as 5600-fold slower than for
unmodified cytosine. We newly determine that fC is a similarly poor substrate (with 3700-fold
discrimination) and that there is no detectable activity of A3A on caC. This level of enzymatic
selectivity suggests little cross-talk between A3A and TET-generated oxidized mC bases (oxmCs) in the genome. We further show that, A3A is remarkably proficient under conditions of
enzyme excess, deaminating all C and mC bases to completion in a long ssDNA substrate
including non-preferred sequence contexts. By contrast, under limiting enzyme conditions, we
find that the well-characterized sequence preferences with unmodified C deamination are
exaggerated with mC. Taken together, our study provides a rigorous, quantitative framework for
understanding the interplay between cytosine methylation, oxidation, and deamination.
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2.3

Materials and Methods

2.3.1

Synthesis of DNA substrates
Oligonucleotides with modified bases (including appropriate modified uracil controls,

aside from fU and 5-carboxyluracil (caU)) were synthesized in-house using an ABI 384
DNA/RNA synthesizer using standard phosphoramidite chemistry and supplier deprotection
protocols (Glen Research). Where necessary, PAGE purifications were performed on the
oligonucleotide substrates; otherwise, DMT-on purifications (GlenPak, Glen Research) were
performed and masses were validated by MALDI-TOF mass spectrometry (Table S2-1). As
phosphoramidites for fU and caU are not commercially available, the fU- and caU-containing
control oligonucleotides were instead synthesized by primer extension (Figure S2-1) using 5formyl-dUTP or 5-carboxyl-dUTP (Trilink Biotechnologies). Complementary strands for the
activity assay were purchased from Integrated DNA Technologies (IDT). Aside from fU and caU
controls, oligonucleotides were either synthesized containing a 3’ FAM group or were postsynthetically labeled with 3’ fluorescein-12-dideoxyuridine (ddU-FAM) using terminal
transferase (TdT) from New England Biolabs (NEB) and ddUTP-FAM (Enzo Life Sciences).
Oligonucleotides used in sequence context experiments were purchased from IDT and
subsequently 3’-ddU-FAM-labeled using TdT.

2.3.2

Expression and purification of recombinant A3A
A3A was amplified from the cDNA plasmid repository (FLH257586.01L, DNASU) and

cloned into a pET41 expression vector with a maltose-binding protein (MBP) N-terminal tag and
a C-terminal 8X histidine tag, both separated from A3A by TEV protease cleavage sites. The
plasmid was transformed into a BL21(DE3) bacterial expression line containing a plasmid
encoding trigger factor to aid solubility (Kohli et al., 2009). Expression in liquid culture was
induced with 1 mM IPTG at OD 0.6. Cells were grown overnight at 16 ºC, pelleted, and lysed by
sonication, and MBP-A3A-His was purified using His-Pur resin (ThermoFisher). Both the N- and
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C-terminal tags were removed by treatment with TEV protease, and the resulting protein was
purified over a HiTrap heparin column (GE Healthcare) using an AKTA FPLC. Purified A3A
was dialyzed into storage buffer containing 50 mM Tris-Cl (pH 7.5), 50 mM NaCl, 10% glycerol,
0.5 mM DTT and 0.01% Tween-20, and stored at -80 ºC.

2.3.3

Qualitative deaminase activity using restriction enzyme-based method
500 nM oligonucleotide substrate was treated with 10-fold dilutions of A3A (from 1 nM

to 1 µM) and allowed to react for 30 minutes in 20 mM Tris-Cl (pH 7.0) and 0.1% Tween-20
(“reaction buffer”) at 37 ºC. Deamination was terminated by incubation at 95 ºC for 20 minutes.
DNA was ethanol precipitated, resuspended in water, and annealed to a 1.5-fold excess of
complementary strand (S35-C-Comp, Table S2-1). SwaI (NEB) was added with appropriate
buffer and incubated overnight at room temperature. The next day, the samples were heat
denatured, run on a preheated 20% acrylamide/TBE/urea gel at 50 ºC, and imaged using FAM
filters on a Typhoon imager (GE Healthcare).

2.3.4

Steady-state kinetic studies of A3A
For improved sensitivity kinetic assays were performed with substrate DNA (10 pmol)

that was 5’-end radiolabeled using T4 polynucleotide kinase (NEB) and 32P-γ-ATP and purified
using Illustra Microspin G-50 columns. Unlabeled DNA at a concentration of 5 µM was added to
~100 nM radiolabeled substrate. For fC and caC substrate, 3’-6-FAM-labeled substrates (as in
qualitative assays above) were used instead of radiolabeled substrates. SwaI assays were
performed as described above, except that substrate concentrations were varied from 80 nM to
1.25 µM (in 2-fold dilutions). A3A concentrations and time intervals for each substrate were
chosen to approximate ~20% deamination with 80 nM substrate at 37 ºC in reaction buffer
(Figure S2-2). The protocol above was followed, except that after ethanol precipitation, reactions
were resuspended in different volumes of water to dilute all samples to 80 nM before annealing
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complement. In the case of the substrates with poor reactivity, we chose time intervals that would
allow us to approximate initial reaction velocities at high substrate concentrations (2 µM), and
then titrated A3A up to 1.4 µM. Specific conditions for each substrate are provided in Figure S22. In the case of 5-iodocytosine (iC), we observed a small portion of unmodified C (validated by
MALDI-TOF) in the sample that arose via deiodonation. As such, we performed digest controls
with uracil DNA glycosylase (UDG, from NEB) on each of the reactions, as UDG does not excise
5-iodouracil, and subtracted the signal resulting from C deamination from each reaction. Also, the
fC substrate was found to undergo some degradation overnight in the SwaI assay, so SwaI
reactions for kinetic determinations were performed for 3 hours at 25 ºC, which still permitted the
fU control to efficiently cleave. For radiolabeled substrates, the gels were exposed to a phosphor
screen for 0.5-4 hours after electrophoresis. The screens were scanned on a Typhoon imager. For
FAM-labeled substrates, the gels were imaged as noted in qualitative assays above. Percent
deamination was calculated by quantifying the intensity of the substrate and product gel bands
using BioRad Quantity One software and then taking the ratio of intensities:
(product)/(product+substrate), with background correction as needed to account for trace
substrate degradation with fC. Michaelis-Menten plots and A3A titration plots were generated
using Prism graphing software. kcat and KM values for C, mC, flC, and brC were calculated
through nonlinear regression fitting to the Michaelis-Menten equation: rate = (kcat)([S])/(KM +
[S]). kcat values for iC, hmC, fC, and caC were determined by linear regression fit on Prism
(Figure S2-3). Reactions were performed in triplicate, and errors are reported as standard
deviations.

2.3.5

Local sequence context preference profile
A 636-bp gene block (IDT) designed to minimize secondary structure was used to

generate single-stranded 636-mer DNAs for the sequence profile experiments using a modified
linear-after-the-exponential (LATE)-PCR protocol (Sanchez et al., 2004), with either unmodified
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dNTPs or 5-methyl-dCTP (Trilink) in place of dCTP, and subsequent

-exonuclease treatment to

degrade the 5’-phosphorylated complementary strand (Figure S2-4). Single-stranded 636-mer
DNA substrates (1 ng), in which all cytosines were either C or mC, were incubated with various
concentrations of A3A (ranging from 200 pM to 2 µM) in reaction buffer for 30 minutes at 37 ºC
and then heat quenched at 95 ºC for 10 minutes. 1 µL of the reaction was used to template PCR
amplification of the DNA using Taq polymerase and internal primers F2 and R2 (Figure S2-4).
Amplified products were run on a 1% agarose gel, extracted, and purified (Gel Extraction Kit,
Zymo). Products were then TA cloned using the TOPO TA cloning kit (Invitrogen), transformed
into Turbo High-Efficiency Cells (NEB), and plated on LB kanamycin plates containing 80
µg/mL X-gal for blue-white screening. After overnight growth, representative white colonies
were miniprepped and sequenced (Genewiz). Deamination events were evidenced by CT
mutations, and local sequence context was recorded for each deamination event. For the analyses
shown in Figure 2-3B and Figure S2-5, data were binned based on the identity of either the -2 or
the -1 base only, without regard for the identity of any other positions. For the analysis in Figure
S2-6, where two positions were combined in analysis, only the cytosine bases in a TTC/mC,
TGC/mC, GAC/mC sequence context were analyzed. Independent reactions under each condition
(each substrate and A3A concentration) were performed in triplicate, with each replicate
incorporating data from 2-4 separate clones per experiment, with errors calculated as standard
deviation between experiments. The fraction deamination was plotted against A3A concentration,
and the effective enzyme concentration to achieve 50% deamination (EC50) was calculated using
hyperbolic fit parameters in Prism graphing software. Under each condition, the fold
discrimination was calculated by taking the ratio of EC50 values for a given base relative to the
most preferred base at that position. For example, at the -1 position, the fold discrimination is
given by the EC50 for A, G or C at the -1 position divided by that of T.
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2.3.6

Sequence context kinetics
For steady-state kinetic experiments on short C substrates in different sequence contexts,

reactions were prepared similarly to conditions detailed above (see “Steady-state kinetic studies
of A3A”), except that ~100 nM radiolabeled substrates were added to 20 µM unlabeled DNA and
substrate concentrations ranged from 80 nM to 5 µM in assays. Conditions were chosen that
would approximate initial reaction velocities for each substrate. For the UDG-coupled assay, after
incubation with A3A for a given time at 37 ºC, reactions were quenched at 95 ºC for 10 minutes,
and then 5 units of UDG were added and incubated at 37 ºC for 2 hours under recommended
buffer conditions. Samples were boiled in formamide loading dye containing 300 mM NaOH and
5 mM EDTA and loaded on a 20% acrylamide/TBE/urea gel for analysis. For A3A titration
experiments on C and mC substrates, a TDG-coupled assay was performed. Substrate was fixed
at 9 µM (>5-fold above the highest calculated KM) and A3A was titrated in serial dilutions.
Reactions proceeded at 37 ºC for 45 minutes before inactivation. Oligonucleotides were ethanol
precipitated and annealed to their respective complement strands (at 1.5X concentrations). TDG,
purified as previously described (M. Y. Liu et al., 2017), was then added in 8X excess of DNA
substrate along with the following 10X buffer: 20 mM Tris pH 8.0, 1 mM DTT, 5 mM EDTA,
0.1 mg/mL BSA. Reactions were incubated at 16 ºC for 12 hours and samples were analyzed as
described in the SwaI assay. All reactions were performed in triplicate on different days, and
errors were calculated as standard deviations.

2.4

Results

2.4.1

Restriction enzyme-based assay for assessing deaminase activity
The catalytic activities of the AID/APOBEC family members have typically been

measured in vitro by exploiting various DNA glycosylases that differentiate between deaminated
cytosine products (uracil analogs) and cytosine substrates. The major limitation of this technique
lies in the glycosylases themselves: many recognizes only a subset of deamination products and
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some, such as TDG, can also excise modified cytosine bases in addition to their deaminated
products. The requirement for multiple different coupling enzymes for probing more than one
modified cytosine functionally makes comparisons between substrates more difficult. Although
some glycosylases such as the thermostable mismatch glycosylase MtMig (Rangam et al., 2012)
have been adapted to examine deamination of several modified cytosine bases, a suitably
selective glycosylase, capable of discriminating deamination of C, mC, hmC, fC, and caC, has not
previously been described.
To overcome these limitations, we developed a uniform method to analyze A3Acatalyzed deamination of all modified cytosine (xC) bases that maintains the selectivity previously
afforded by glycosylases, ensuring efficient detection of uracil analog products (xU) while
minimizing background activity on their cytosine substrates. To this end, we synthesized a series
of oligonucleotides, 35 bases in length, containing either the TTxCA substrate sequence or
TTxUA as the corresponding product. We focused on this sequence context, as TTCA is a
preferred substrate for A3A (Logue et al., 2014). We surveyed a series of restriction enzymes that
displayed altered cleavage patterns in response to a TTxCA to TTxUA change to find one that
retained this capability regardless of the modification. We found the desired properties in SwaI,
which normally cuts at ATTTAAAT recognition sequences (Figure 2-2A). Interestingly, when
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the complementary strand contains the matched complementary SwaI restriction site intact, both
the xC-containing and xU-containing duplexes are cleaved to some extent. However, when the

Figure 2-2. Qualitative activity of A3A using a restriction-enzyme based assay.
(A) 3’-FAM-labeled single-stranded oligonucleotides containing one substrate cytosine in an
ATTxCAAAT sequence context are treated with A3A. A complementary strand is annealed, with G
paired across from the substrate xC (mismatched if deaminated to xU). SwaI recognizes and specifically
cleaves only the 5’-ATTxUAAAT in this context, allowing the labeled unreacted 35-mer substrate
(S35) to be separated from cleaved, deaminated 16-mer product (P16) on a denaturing polyacrylamide
gel imaged with FAM filters. (B) A3A titrations on substrates containing C, mC, or ox-mCs. In each
gel, from left to right are incubations of each substrate (500 nM) with 0, 1, 10, 100, and 1000 nM A3A
(37 ºC for 30 min). When noted, the rightmost lane is a product control without A3A. Product controls
for the fC/caC reactions are shown in Figure S1. Degradation of the fC substrate with prolonged
incubation produces a band (*) at the same size as P16 product, requiring background correction in
quantification of deamination. Deamination of fC is above background at 1000 nM A3A. (C) A3A
reactions with substrates containing with 5-halogenated cytosines are shown in an analogous format.

complementary oligonucleotide contains a mismatched G on the opposite strand, sensitive
discrimination between all uracil and cytosine analogs is achieved (Figure S2-1). This
phenomenon of mismatch recognition of some restriction enzymes has been observed previously
(Langhans and Palladino, 2009). Interestingly, consistent with the tolerance for various xU
modifications we observe, a recently solved structure of SwaI in complex with DNA (B. W. Shen
et al., 2017) reveals a lack of steric interactions with the 5-methyl group of T at the center of the
cleavage recognition site (see additional discussion provided in Figure S2-1).
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2.4.2

Qualitative activity of APOBEC3A on modified cytosines
Using our SwaI-based assay, we first qualitatively examined the activity of A3A on the

five physiological cytosine modification states in DNA (C, mC, hmC, fC, and caC). 500 nM of
each labeled ssDNA substrate was treated with serial 10-fold dilutions of A3A. After the reaction,
strands were annealed to the mismatched complement. The duplexes were then digested with
SwaI, and the cleaved xU-containing products were separated from uncleaved xC-containing
substrates on denaturing gels (Figure 2-2B). As expected, the unmodified C substrate showed
partial deamination at even the lowest A3A concentration chosen (1 nM) and was fully
deaminated with 10 nM A3A under these conditions. In line with previous reports showing high
mC activity (Carpenter et al., 2012; Suspene et al., 2013; Wijesinghe and Bhagwat, 2012), the
mC substrate also showed signs of deamination at low A3A concentration, though complete
deamination was not achieved until treatment with 100 nM A3A. hmC- and fC-containing oligos
were resistant to deamination at low concentrations of A3A, but discernable deamination was
detected at the highest concentrations of A3A tested (1 µM). In contrast, no deamination of caCcontaining substrate was detected, even at the highest A3A concentrations evaluated.
In general, the pattern of activity by A3A follows a steric trend of discrimination
previously observed with human AID, mouse APOBEC1, and mouse APOBEC3, in which larger
5-substituents were disfavored (Nabel, Jia et al., 2012). In order to probe this steric trend further,
we synthesized analogous substrates containing 5-halogenated cytosines of various sizes and
electrochemical properties. When these substrates were tested with the SwaI-based assay, we find
that the patterns observed with natural cytosine substrates are maintained at a qualitative level
(Figure 2-2C). Iodo-C (iC) shows a similar level of deamination to hmC, which correlates with its
size, while bromo-C (brC) shows an expected intermediate level of deamination between mC and
hmC/fC. In line with its small size, 5-fluorocytosine (flC) is deaminated proficiently, to a roughly
similar extent as mC.
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2.4.3

Steady-state kinetics of APOBEC3A on modified cytosines
Given the overall high activity of A3A on C and several 5-modified cytosines, we posited

that our SwaI-based assay should permit steady-state kinetic analyses for rigorous quantitative
comparisons between substrates. Also, since our qualitative assays are the first to note low-level
A3A activity on hmC and fC, a sensitive approach could newly allow for accurate quantification
of the extent of discrimination against ox-mCs by A3A. To this end, reactions were set up to
achieve steady-state conditions and meet necessary assumptions to fit the data with MichaelisMenten parameters (Figure S2-3). Rates of A3A-mediated deamination were obtained for a range
of concentrations of the smaller modified substrates (C, mC, flC, and brC), and fitted to obtain
kcat and KM values (Table 2-1). Our quantitative analysis demonstrates high A3A activity on
unmodified cytosine (kcat/KM = 79 µM-1min-1), and decreasing kcat/KM values with increasing size
of substituent. We noted that the differences in activity were predominantly due to a catalytic
effect: the kcat values changed significantly across the substrate series while the KM values
remained relatively similar (310-550 nM). Intriguingly, a subtle but quantifiable exception to the
observed steric trend was manifested in the calculated kcat/KM values of flC and mC. Though our
qualitative assay showed little difference in activity between these two substrates, we calculated a
lower kcat/KM for the smaller flC (16 µM-1min-1) than for the larger mC (25 µM-1min-1),
supporting the previous observations that A3A has a particular predilection for mC deamination.
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Due to the lower activity on the larger, oxidized substrates, steady-state assumptions
could not be readily achieved at low substrate concentrations. However, extrapolating from our
observation that the KM values are not substantially altered across the different substrates tested,
we fixed substrate concentrations at a saturating level (2 µM) and titrated enzyme to calculate the
presumptive kcat values (Table 2-1). Most of the larger and/or oxidized modifications show very

Table 2-1. Kinetic constants for A3A acting on modified cytosine substrates.
* The size of each substituent (in Å3) was calculated using SPARTAN molecular modelling
software.
† kcat and KM values were determined for the smallest four substrates (C, flC, mC, and brC) by
performing steady-state kinetic measurements. kcat values were approximated for the four largest
substrates (fC, iC, hmC, and caC) by determining the observed rate at saturating substrate
concentrations. As no activity was detected on caC, the value reported corresponds to the calculated
detection limit (determined in Figure S2C). n.c., not calculated. Errors are reported as standard
deviations from three independent kinetic replicates.
†† Relative activities are calculated as the ratio of kcat values, with associated error calculated from
propagation of error in kcat values.

little, though detectable, activity, and there is no detectable activity on caC. The kinetic analysis
suggests that, relative to deamination of unmodified C, deamination of hmC is ~5600-fold less
proficient and fC deamination is ~3700-fold less proficient. Even with large excess of A3A and
long incubation time, caC showed no detectable deamination, which suggests a >20000-fold
discrimination against caC based on our calculated limits of detection for caU (Figure S2-2C).
Thus, despite its notable activity on mC, our kinetic analysis provides the first evidence that A3A
potently discriminates against all three TET-oxidized products of mC.
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2.4.4

Activity of A3A on Cs and mCs across all sequence contexts
While discrimination against ox-mCs holds significant implications for models of DNA

demethylation involving coupled oxidation and deamination, the proficiency of mC deamination
raises the question of how such activity might manifest on genomic substrates. The target
substrates of DNA deaminase activity are conjectured to be long ssDNA stretches that arise from
processes such as DNA replication, DNA repair, or telomere crisis (Green et al., 2016; Kazanov
et al., 2015; Maciejowski et al., 2015; Roberts et al., 2012), and sequence preferences have been
one of the most important features defining AID/APOBEC activity at these sites. We therefore
next asked if proficiency with mC deamination would extend to more complex substrates and if
local sequence context would differentially influence A3A’s ability to target C versus mC for
deamination. To this end, we generated long 636-mer single-stranded DNA substrates (Figure S24) containing exclusively either C or mC using a modified version of linear-after-the-exponential
PCR (Sanchez et al., 2004). These extended ssDNA substrates (1 ng) were treated with increasing
concentrations of A3A, and individual strands were then PCR amplified, cloned, and sequenced.
This assay approach readily demonstrates the efficiency of A3A in both C and mC
deamination. In the case of the C-containing substrate, we were surprised to find that at the
highest concentration of A3A evaluated, every single C could be deaminated to completion in all
clones (Figure 2-3A; all 183 C bases in each of 9 clones), a phenomenon that has yet to be
described in the literature with any AID/APOBEC deaminase. We observed similar levels of
deamination in the mC-containing substrate at the highest A3A concentrations, although complete
deamination was not as consistent across all clones. Complete deamination was observed in 6 of
18 clones and the other clones were deaminated to near-completion (83.1-99.5%).

35

Examining deamination at lower concentrations of A3A permitted a more nuanced
analysis of the proficiency of C versus mC deamination in various sequence contexts. For
AID/APOBEC family enzymes, the upstream bases are known to be the strongest determinants of
deamination efficiency, with a dominant role for the -1 base and a secondary role for the -2 base;
the immediate downstream +1 position is also known to contribute to specificity to a lesser extent
(Langlois et al., 2005; Logue et al., 2014). We therefore categorized each target cytosine based
upon the identity of the -2, -1 and +1 bases and then plotted the fraction of deaminated cytosines
in each context (Figure 2-3B and 2-3C, Figure S2-5). For a quantitative comparison of A3A
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Figure 2-3. Deamination of long, single-stranded substrates
(A) 1 ng of single-stranded 636-mer DNA substrates containing either unmodified bases or mC in
place of all cytosines were treated with various concentrations of A3A and then were clonally
sequenced. Plotted are the fractions of deaminated bases as a function of A3A concentration. Each
data point represents the average from at least three independent experiments, with each experiment
containing 2-4 clones sequenced under that condition. The standard deviation is calculated between
the independent experiments. Both C- and mC-containing substrates can be fully deaminated at the
highest concentrations of A3A. The EC50 is the enzyme concentration to achieve 50% deamination
of all C or mC bases and was calculated by fitting each curve to a hyperbolic function. The effect of
local sequence context was examined by separately analyzing deamination efficiency for (B) the -2
position relative to the target base or (C) the -1 position relative to the target base. Each position is
considered independently of the other position, and X denotes any base. The fold discrimination is
the ratio of EC50 for a given base, relative to that of the preferred T at the same position.

activity, we defined the EC50 as the effective concentration of A3A required to achieve
deamination of 50% of C or mC bases in that context; we normalized each EC50 relative to that
for the preferred base at each respective site. As anticipated, the ability of A3A to deaminate
cytosines depends most heavily on the -1 base. In the case of -1 preferences with C substrates, we
observe a 2.4-fold discrimination of CC compared to TC and an even more pronounced 9.2- or
12-fold discrimination against GC and AC, respectively. In the case of the mC substrates, the
relative EC50 values shift to 2.6-fold, 15-fold, and 16-fold for CC, GC, and AC, respectively.
Thus, the influence of the -1 substituent is mildly exaggerated in the case of mC relative to C,
with a wider span of EC50 values. The data for the -2 base, which has a less significant influence
on activity, shows a subtle but similar trend, with a wider span of EC50 values for mC than for C
(Figure 3B). The +1 base also shows only a minor influence on deamination efficiency, with
similar patterns of EC50 values for C and mC (Figure S2-5). Given the dominant role for upstream
bases, we also examined the effect of combining the -2 and -1 positions in analysis rather than
treating the two positions independently (Fig S2-6). In the preferred sequence context (5’TTC/mC) the EC50 ratio reflects a 5.9-fold preference for C versus mC deamination, while this
ratio increases to 10-fold for deamination in the least preferred GAC/mC context.
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The observed shift in sequence preferences with C versus mC substrates prompted us to
ask how sequence context and methylation status combine to determine deamination efficiency in
shorter oligonucleotide substrates. To this end, we synthesized a matched set of six
oligonucleotides that differed in the local sequence context—preferred (TTC/mC), intermediate
(TGC/mC), or disfavored (GAC/mC)—along with the associated product controls. With the
cytosine-containing substrates, we again verified that the major differences in deamination
efficiency were largely attributable to kcat (Figure S2-7), and turned to a TDG-coupled assay
under saturating substrate concentrations to compare the relative reactivity of C and mCcontaining substrates (Figure 2-4). Similar to the results seen with the SwaI-based assay, we
observed a 2.5-fold drop in kcat with the TTmC-containing substrate relative to TTC-containing
substrate. In the intermediate and disfavored sequence contexts, we noted 8.0-fold discrimination
between TGC and TGmC and 13-fold discrimination between GAC and GAmC. The skew in

Figure 2-4. Enzyme titrations on C and mC substrates in various sequence contexts
9 µM oligonucleotide substrate in a preferred (TTC/mC), intermediate (TGC/mC), or disfavored (GAC/mC) sequence
context was incubated with various amounts of A3A and product formation quantified using a TDG-coupled assay.
Experiments were performed in triplicate, with error bars indicating standard deviation between experiments, and values
were fit with linear regression. Observed rates were calculated as the slope, reflecting the presumptive kcat values.

sequence preferences with the long 636-mer (5.9-fold with TTC/mC versus 10-fold with
GAC/mC) is even more apparent with oligonucleotide substrates (2.5-fold in TTC/mC versus 13fold in GAC/mC). This difference could be attributable to the nature of A3A interactions with a
long substrate containing multiple cytosine bases that could alter rate-determining steps in
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deamination. Nonetheless, as we consistently observed a larger C/mC discrimination in nonpreferred substrates, we conclude that the sequence context and the modification state of the
cytosine base together influence the overall activity of A3A on target bases.

2.5

Discussion
Recent studies have implicated enzymatic deamination of cytosine and epigenetically-

modified cytosine bases in diverse processes including DNA demethylation and cancer
mutagenesis. We focused on characterizing the activities of A3A specifically given prior
evidence of enhanced activity on mC. To this end, we devised a deamination assay that permitted
parallel, quantitative comparisons of A3A activity on the cytosine variants in DNA. Using this
approach, we found, in line with prior studies, that mC is efficiently deaminated by A3A, with
only a ~4-fold decrease in kcat relative to unmodified cytosine in the preferred sequence context.
While prior studies on AID/APOBEC family members using less sensitive or semi-quantitative
assays suggested that hmC cannot be deaminated by DNA deaminases (Nabel, Jia et al., 2012;
Rangam et al., 2012; Suspene et al., 2013), our assays indicate that deamination can occur, albeit
at rates ~5600-fold reduced relative to unmodified cytosine. Our approach also allowed us to
evaluate deamination of fC and caC for the first time with any DNA deaminase. We report strong
discrimination against fC, and no detectable activity on caC.
We can gain mechanistic insight into our findings by considering the recent crystal
structure of A3A solved in complex with ssDNA (Shi et al., 2017). The structure revealed that the
cytosine base is rotated away from stacking with neighboring bases and inserted into a deep
active site pocket where the C5-C6 side of the base abuts a hydrophobic phenolic ring of tyrosine
(Y130). This Y130 residue likely serves as the “steric gate” in the active site, providing a
mechanism for the observed discrimination against bulkier 5-position substituents. Although the
trend of steric discrimination generally holds, A3A deaminates mC more efficiently than the
smaller 5-fluorocytosine (flC). This minor deviation could be explained by enhanced hydrophobic
39

interactions between the methyl substituent and Y130 that are lost in the case of the
electronegative flC. Such active site steric constraints on deamination of 5-modified cytosines are
not universal in the larger deaminase superfamily beyond AID/APOBECs. Unlike A3A, cytidine
deaminase (CDA), a related enzyme that deaminates free cytidine nucleosides rather than
cytosine bases in DNA, can efficiently deaminate the nucleosides of hmC and fC (Zauri et al.,
2015). Given that AID/APOBECs bind and deaminate cytosines as part of longer DNA
substrates, it is likely that the flexibility constraints on the cytosine base prevent access to the
alternative orientations that permit CDA to deaminate ox-mC nucleobases (Shi et al., 2017).
While prior cell-based studies have suggested that deamination of ox-mCs could
contribute to DNA demethylation (Cortellino et al., 2011; Guo et al., 2011; Xue et al., 2016), our
work indicates that these pathways are biochemically disfavored. As A3A has the highest activity
on mC among the AID/APOBEC family members, the enzyme’s potent discrimination against
ox-mCs is particularly compelling. Given these results, we therefore suggest that it is unlikely
that DNA deaminases play a major role in demethylation via an oxidation-deamination
mechanism (Ito et al., 2011). This conclusion does not eliminate the possibility that other factors,
such as protein interaction partners or post-translational modifications, could change the local
concentration of the enzyme near a given substrate or otherwise impact activity; however, such
factors have yet to be demonstrated. Also, it remains plausible that AID/APOBECs could play a
role in active DNA demethylation via activity on mC bases, as suggested in certain cell and tissue
types (Bhutani et al., 2010; Cortellino et al., 2011; Morgan et al., 2004; Rai et al., 2008). Such
demethylation could involve direct deamination of mC by DNA deaminases, or, alternatively,
patch repair of bases neighboring the site of either C or mC deamination (Franchini et al., 2014).
To characterize C and mC deamination activity further, we expanded from simple
oligonucleotide substrates with a single target base to longer, more complex ssDNA substrates.
Importantly, in these assays on lengthy single-stranded C- and mC-containing substrates, we
observed that A3A can fully deaminate substrates containing Cs or mCs across all sequence
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contexts in vitro. To our knowledge this is the first demonstration of such proficiency with any
AID/APOBEC deaminase, raising the prospect of its utility as a biotechnological tool to
distinguish between epigenetic cytosine modification states. Shortly after the initial discovery of
AID, the concept of using DNA deaminases to discriminate between C and mC bases as part of
epigenetic sequencing approaches was suggested (Morgan et al., 2004); however, the poor overall
activity of the enzymes and lack of sufficient discrimination between C and mC across all
sequence contexts prevented their application as bisulfite-like mC sequencing tools (Bransteitter
et al., 2003). Revisiting those suggestions in light of our new results, efficient deamination of
C/mC by A3A and potent discrimination against ox-mCs could now be exploited to localize
modified bases at single-base resolution in genomic DNA.
Our study on both long and short DNA substrates in various sequence contexts
demonstrates that sequence preferences of C deamination are exaggerated with mC deamination.
In oligonucleotide substrates, while the C:mC deamination ratio was ~3:1 when in the preferred
sequence context, it increased to ~13:1 when in a highly-disfavored context. This phenomenon is
potentially important to account for when interpreting the AID/APOBEC mutational signatures in
cancer sequencing projects. First, while most sequencing studies attribute deamination in CpG
contexts predominantly to spontaneous deamination of mC, enzymatic deamination resulting
from aberrant expression of A3A could also play a role in deamination of mC, especially when
mC is in A3A’s preferred sequence contexts (i.e. YmCpGs). As most methylation exists in a CpG
context in the genome, it was particularly notable that deamination of mCpG was only ~1.4-fold
less efficient relative to the most preferred mCpA and mCpC contexts. Second, separately
evaluating the mutational signature in CpG and non-CpG contexts might provide an added means
to distinguish the impact of A3A from that of A3B (Burns, Lackey et al., 2013; Chan et al., 2015;
Starrett et al., 2016), especially since A3B has been shown to have minimal activity on mC (Fu et
al., 2015; Siriwardena et al., 2015).
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In mammalian genomes, cytosine bases are the focus of potentially intersecting
modifications, with various permutations of cytosine methylation, deamination, and oxidation.
Overall, our results reveal the intrinsic preferences of a DNA deaminase, helping to narrow the
scope of potentially relevant in vivo modifications. Unmodified C can be methylated or
deaminated; mC can be deaminated or oxidized; but the ox-mC bases—hmC, fC, and caC—are
not subject to significant deamination. While the local sequence context is one feature which
further impacts the nature of modifications on a target base, ongoing studies to understand the
interplay of these various DNA modifying processes in immunity, epigenetics, and cancer
biology remain an important priority.
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CHAPTER 3: Exploiting the Activity of A3A on the Extended Epigenome in APOBECCoupled Epigenetic Sequencing (ACE-Seq)

This chapter has been adapted from the following manuscript:
Schutsky E.K., DeNizio J.E., Hu P., Nabel C.S., Hwang Y., Bushman F.D., Wu H., Kohli
R.M. (2018). APOBEC-Coupled Epigenetic Sequencing permits low-input, bisulfite-free
localization of 5-hydroxymethylcytosine at base resolution. Nature Biotechnology. In
revision.3

3.1

Abstract
Here we present APOBEC-Coupled Epigenetic Sequencing (ACE-Seq), a bisulfite-free

method for localizing 5-hydroxymethylcytosine (hmC) at single-base resolution with low DNA
input. The method builds upon our observation that AID/APOBEC family DNA deaminase
enzymes can potently discriminate between cytosine modification states, and exploits the nondestructive nature of enzymatic, rather than chemical, deamination. ACE-Seq yields highconfidence hmC profiles with at least 1000-fold less DNA input than conventional methods. We
apply ACE-Seq to generate the first base-resolution map of hmC in tissue-derived cortical
excitatory neurons. We find that hmC is almost entirely confined to CG dinucleotides, and
resolving C, mC and hmC reveals that regions appearing heavily methylated can be highly
enriched for hmC. Enzymatic deamination overcomes many challenges posed by bisulfite-based
methods and expands the scope of epigenome profiling by permitting characterization of scarce

3
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samples that will open new lines of inquiry regarding the role of cytosine modifications in
genome biology.

3.2

Introduction
Epigenetic modifications of cytosine bases are crucial for proper regulation of gene

expression in mammals (Schubeler, 2015). While 5-methylcytosine (mC) is best characterized for
its gene repressive roles, the types of known modifications were greatly expanded with the
identification of several oxidized forms of mC (ox-mCs) that arise through the action of teneleven translocation (TET) family enzymes (He et al., 2011; Ito et al., 2011; Pfaffeneder et al.,
2011; Tahiliani et al., 2009). Ox-mCs serve as intermediates in active DNA demethylation,
whereby repressive mC marks are erased; ox-mCs may also have independent epigenetic
functions (Kohli and Zhang, 2013). 5-hydroxymethylcytosine (hmC) can reach as high as 40% of
the levels of mC in some cell types, such as cerebellar Purkinje neurons (Kriaucionis and Heintz,
2009). The highly oxidized bases 5-formylcytosine (fC) and 5-carboxylcytosine (caC) are also
detected but are far less common, comprising ~1 in 105-6 cytosines in most cell types (Bachman et
al., 2015; He et al., 2011; Ito et al., 2011; Pfaffeneder et al., 2011).
The most commonly-used approaches for localizing cytosine modifications rely upon
differential chemical reactivity of cytosine variants in bisulfite sequencing (BS-Seq) (Figure 3-1a)
(Wu and Zhang, 2015). Incubation of DNA with bisulfite at extreme pH and elevated temperature
promotes deamination of cytosine to uracil, while mC is largely unaffected (Figure S3-1). With
the discovery of ox-mCs, the interpretation of BS-Seq became more complicated: While fC and
caC rapidly deaminate in BS-Seq, hmC forms a bulky adduct that is slow to deaminate, rendering
hmC indistinguishable from mC (Y. Huang et al., 2010). In order to localize hmC specifically,
several techniques have been advanced to change the bisulfite reactivities of mC versus hmC. In
TET-assisted bisulfite sequencing (TAB-Seq) (Yu, Hon, Szulwach, Song, Zhang et al., 2012),
hmC bases are enzymatically modified by glucosylation (yielding ghmC), and mC is then
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selectively oxidized to caC in vitro by TET. Upon bisulfite treatment, all bases except the
protected ghmC are deaminated. Alternatively, oxidative bisulfite sequencing (oxBS-Seq)
employs selective oxidization of hmC to fC before bisulfite conversion (Booth et al., 2012).

Figure 3-1. Reactivities of modified cytosines in sequencing approaches
(a) Deamination underlies the differentiation of modified cytosines in current sequencing
approaches. Standard BS-Seq converts cytosine to uracil and leaves mC and hmC
unconverted, reading as C in sequencing. Modifications to mC and hmC in oxBS-Seq and
TAB-Seq, when coupled to bisulfite, can differentiate these two bases. ACE-Seq uses
enzymatic rather than bisulfite-mediated deamination to provide an similar readout to TABSeq. (b) In the optimized ACE-Seq protocol, APOBEC3A catalyzes the enzymatic
deamination of C and mC to completion, while hmC, which is highly resistant to
deamination but is further protected by glucosylation, is localized by its non-conversion.

Subtraction of oxBS-Seq signals from standard BS-Seq signals allows for indirect identification
of hmC.
A key limitation of these methods is the use of bisulfite – chemical deamination
conditions can degrade as much as 99.9% of input genomic DNA (gDNA) (Tanaka and Okamoto,
2007), and exploring rare cell populations undergoing dynamic epigenetic changes can therefore
be challenging. Thus, when samples of gDNA are limiting, experiments using reduced
representation or enrichment steps are often performed, rather than whole-genome sequencing
(Clark et al., 2016). The characterization of specific primary cell types has likewise been
challenging, emphasizing the importance of methods that permit low amounts of starting DNA.
For hmC detection, methods that avoid the use of bisulfite have been pursued, including
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nanopore, single-molecule real time (SMRT), and restriction enzyme-based approaches (Booth et
al., 2015; Chavez et al., 2014; Z. Sun et al., 2013; Zahid et al., 2016). However, the limitations of
each method have contributed to conflicting results, leaving, for example, the prevalence and
significance of hmC in non-CG sites a matter of debate (Gross et al., 2015; Lister et al., 2013;
Mellen et al., 2017; Z. Sun et al., 2015).
Recognizing the constraints of chemical deamination, we were drawn towards a natural
analog of this reaction: enzymatic deamination by an AID/APOBEC family DNA deaminase.
Here, we report the development, validation, and application of APOBEC-Coupled Epigenetic
Sequencing (ACE-Seq). In our approach, deamination under near-physiological, nondestructive
conditions permits single-base resolution hmC profiling with minimal DNA input.

3.3

Results

3.3.1

Development of ACE-Seq
Members of the AID/APOBEC family catalyze the deamination of cytosine to uracil in

single-stranded DNA (ssDNA) and mediate critical functions in innate and adaptive immunity
(Siriwardena et al., 2016). In prior work, we found that several family members can discriminate
between cytosine modification states (Nabel, Jia et al., 2012); however, their overall poor
catalytic activity prevented biotechnological applications. More recently, motivated by
subsequent studies demonstrating that one human-specific family member, APOBEC3A (A3A),
has high activity and a particular proficiency for mC deamination (Carpenter et al., 2012;
Wijesinghe and Bhagwat, 2012), we turned our attention to quantifying A3A’s activity on the full
spectrum of natural cytosine modifications. We found that A3A indeed readily deaminates C and
mC, but also discriminates potently against all three ox-mCs, with the hmC deamination rate
~5000-fold reduced relative to that of C deamination (Schutsky, Nabel et al., 2017). This
observation raised the prospect that A3A’s differential reactivity could be exploited to localize
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hmC in gDNA, achieving a sequencing readout similar to that of TAB-Seq without the need for
bisulfite.
We envisioned three potential barriers to using AID/APOBECs in sequencing. First,
enzymatic deamination, like chemical deamination, requires ssDNA; unlike in BS-Seq, gDNA in
ACE-Seq would need to be denatured under mild conditions that permit enzymatic activity.
Second, different AID/APOBEC family members show distinctive sequence preferences, with 5’
bases influencing activity most strongly. A3A, for example, preferentially deaminates TTC, with
activity reduced ~16-fold in disfavored contexts 22. In ACE-Seq, sequence context preferences
would have to be overcome. Third, ACE-Seq would require a sufficient window of enzymatic
selectivity such that false-positive (C/mC non-conversion) and false negative (hmC conversion)
readouts were minimized.
As a model system to develop ACE-Seq, we used phage gDNA, given that these genomes
offer known, homogenous modifications (Figure S3-2). The 169-kb T4 phage genome normally
contains all cytosine bases replaced by ghmC (WT, here referred to as T4-ghmC). Established
mutants in the ghmC pathway yield phage in which every encoded C is hmC (referred to as T4hmC) or where all C bases are unmodified (referred to as T4-C)(Bryson et al., 2015). To first
evaluate conditions for ssDNA generation, we explored deamination of T4-C. Following brief
heat denaturation and snap freezing of 1 ng gDNA and subsequent incubation with excess A3A (5
µM), a target locus was amplified, cloned, and sequenced. In initial trials, while all clones were
highly deaminated, small regions correlating with regions of high secondary structure were
protected from deamination (Figure S3-3). To minimize secondary structure formation, we
denatured in the presence of DMSO and performed A3A incubation under ramping temperature
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conditions. Under these optimized conditions, the T4-C locus was entirely converted,
demonstrating the proficiency of enzymatic deamination of unmodified C residues (Figure 3-2a).

Figure 3-2. Locus-specific validation of ACE-Seq
(a-c) 1 ng of T4 phage genomic DNAs with homogeneous modifications (a: T4-C; b: T4hmC; c: T4-ghmC) were heated, snap frozen, and incubated with A3A before TA cloning
and Sanger sequencing individual clones. Representative sequencing traces below the
reference genome are shown. Arrows denote deamination events (C>T transitions).
Deamination events are quantified as the number of cytosines that were deaminated across
the sum of all clones (93 cytosines per clone). Sequence context profiles are denoted for the
positions 5’ to the deaminated cytosines where the colors match those of the reference
sequence (C, blue; A, green; T, red; G, black) (d,e) Rates of non-conversion for synthetically
methylated l phage gDNA (mCG, CH) and T4-hmC phage gDNA in ACE-Seq, using inputs
of either (d) 1 ng of each alone or (e) 100 pg each as spike-ins averaged across six mammalian
DNA samples (see Table S3-1). Mean values listed above each bar.

When these conditions were next applied to T4-hmC, the majority of hmC bases were
protected from deamination (Figure 3-2b); however, some hmC deamination events were
observed (~10%). These events aligned with A3A preferences (i.e. mostly at TThmC sites),
validating our prior observation that hmC can be deaminated by excess A3A, albeit
inefficiently(Schutsky, Nabel et al., 2017). As we have previously shown that AID/APOBECs
discriminate against bulky 5-position modifications(Nabel, Jia et al., 2012; Schutsky, Nabel et al.,
2017), we considered whether further modification of hmC could protect it from deamination.
Consistent with this hypothesis, under conditions that yielded complete T4-C deamination, we
observed no deamination of T4-ghmC at any position (Figure 3-2c). Therefore, we posited that in
vitro glucosylation of hmC in gDNA could be used to prevent its sporadic deamination by A3A.
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To investigate the efficiency of mC deamination, we pooled T4-hmC phage gDNA with
lambda () phage gDNA (48.5-kb) synthetically methylated at all CG sites (Figure S3-2c). The
gDNA was sheared, and a low input sample (1 ng) was treated with T4 β-glucosyltransferase
(βGT) to convert hmC to ghmC, followed by incubation with excess A3A. The resulting products
were analyzed using Illumina high-throughput sequencing after library preparation. For the whole
genome analysis with synthetically-glucosylated T4-hmC phage, the results mirrored those of our
locus-specific analysis on T4-ghmC: the gDNA was protected from deamination, with ~99.4% of
all hmC bases called as C in sequencing (Figure 3-2d), which exceeds the sensitivity of TAB-Seq
(84.4-92.0%) (Lister et al., 2013; Mo et al., 2015; Yu, Hon, Szulwach, Song, Zhang et al., 2012).
Unbiased analysis of the λ phage genome showed robust C/mC deamination. Non-conversion of
C or mCG was detected for only ~6,800 of 2.4 million independently sequenced C sites and
~10,500 of ~800,000 mCG sites, respectively (Figure 3-2d, Table S3-1). The C and mC nonconversion rates (0.3% and 1.3%, respectively) are similar or better than those observed with
TAB-Seq (0.4%; 2.2%) on a comparable λ gDNA control (Yu, Hon, Szulwach, Song, Zhang et
al., 2012).
Thus, regarding the three barriers initially considered, in our optimized ACE-Seq
protocol (Figure 3-1b) a modified denaturation protocol permitted A3A to access its ssDNA
substrate, and driving conditions with excess A3A allowed full C/mC deamination in all sequence
contexts. While these conditions resulted in some hmC deamination, these bases could be fully
protected from low-level deamination by glucosylation to generate a wide window for C/mC
versus hmC discrimination.

3.3.2

ACE-Seq is non-destructive
Before moving ACE-Seq forward to hmC profiling of complex mammalian samples, we

first wanted to confirm and characterize the non-destructive nature of the approach compared to
standard bisulfite treatment. In typical bisulfite-based approaches, template gDNA damage limits
49

the size of amplicons that can be characterized, with amplicons typically <300 bp in the length
(Warnecke et al., 2002). To compare the impact on template gDNA, mouse embryonic stem cell
(ESC) gDNA was treated with either BS-Seq or ACE-Seq conditions. After deamination, we
attempted to amplify either short (~200-bp) or long (~1-kb) amplicons from a single target locus
(Tbx5) using a fixed number of PCR cycles. For the short amplicon, while the ACE-Seq sample
was more readily amplified, amplicons could be detected below 10 ng input gDNA with either
condition (Figure 3-3a). However, with the ~1-kb locus, ACE-Seq amplicons were detectable
with ~3-log lower DNA input, suggesting that BS-Seq had introduced damaged sites in ~99.9%

Figure 3-3. ACE-Seq is nondestructive
Initial input levels of gDNA from mESCs were titrated from 1 µg to 1 ng, and the samples were treated
with either BS-Seq or ACE-Seq protocols. Primers were designed to amplify either (a) a ~200-bp
amplicon or (b) a ~1-kb amplicon from the Tbx5 genomic locus, using 35 cycles of PCR. Resulting
amplicons were run on 1.5% agarose gels and stained with SybrSafe.

of the template strands in this region (Figure 3-3b). In contrast, ~1-kb amplicons with ACE-Seq
were detected at the same low input as the ~200-bp amplicons, suggesting that gDNA is intact
under ACE-Seq conditions.

3.3.3

ACE-Seq detects true positive hmC bases
We next characterized hmC at single-base resolution in mammalian cells. To highlight

ACE-Seq’s utility on a specific tissue-derived cell subtype, we isolated gDNA from purified
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murine cortical excitatory neurons (NeuroD6/NEX+) (Johnson et al., 2017), which allowed
comparison to gDNA from total mouse brain cortex previously characterized by TAB-Seq(Lister
et al., 2013). To assess specificity, gDNA was also purified from wild-type and TET-triple
knockout (TKO) mouse ESCs, the latter of which should have no authentic hmC. For each
sample, gDNA was spiked with 0.5% of T4-hmC and CG-methylated

phage gDNA as internal

controls. We then subjected either 2 or 20 ng of DNA to our optimized ACE-Seq protocol and
sequenced to an average depth of ~8-11x per strand, comparable to previous TAB-Seq
experiments (Table S3-1). Reads were aligned against the mouse genome and complete strandspecific base-resolution hmC maps were established for each of the three samples (Figure 3-4a).
Analysis of the spike-in controls confirmed an average non-conversion rate of hmC (98.5%)
versus C/mC (0.1% and 0.5%, respectively), which permitted robust hmC discrimination (Figure
3-2e).
We first focused our analysis on the raw hmC signal detectable in the CG context. We
analyzed the signal in 1-kb tiles and found that hmCG is highly abundant in the cortical excitatory
neurons, and relatively lower in mESCs, as anticipated (Figure 3-4b). Given the high prevalence
in neurons, we performed a pairwise comparison between the hmC signal from ACE-Seq in
cortical excitatory neurons and that from TAB-Seq of the total brain cortex and found a strong
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Figure 3-4. Generation of whole genome base-resolution maps of hmC using ACE-Seq
(a) Snapshot of base-resolution hmC maps (ACE-Seq or TAB-Seq: red/blue for positive (Watson)/
negative (Crick) strands, respectively) compared to DNA immunoprecipitation-based hmC map (DIPSeq: pink) near the Tet1 gene locus (chr10:62,262,357-62,300,848; genome build: mm9). Only CGs
sequenced to depth >=2 are shown. Gray tracks denote sequencing coverage for each position. (b) Violin
plots comparing raw hmCG signals (fraction of C/(C+T)) within 1-kb genomic bins between ACE-Seq
(red) or TAB-Seq (blue) in mouse ESC (left) or neurons (right). Mean values are above each plot. (c)
Correlation density plot between ACE-Seq signals (within 10-kb bins) in neurons and TAB-Seq signals
in frontal cortex. a.u., arbitrary units. (d) Bar graph of statistically-significant hmCG sites in wild-type
(WT) mouse ESCs, TET TKO mouse ESCs, and WT cortical excitatory neurons. (e) Sequence context
of statistically-significant hmC sites (in WT excitatory (ex) neurons) compared to the reference mouse
genome. (f) Violin plot of the distribution of modification levels of called hmCG, hmCHH, and hmCHG
sites in WT ex neurons. Mean values are listed above the plot.

correlation (Figure 3-4c, Pearson correlation coefficient 0.92), in agreement with the fact that the
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cortex contains about 85% excitatory neurons. Importantly, the ACE-Seq hmC map was
generated using only 2 or 20 ng of input gDNA in comparison to the TAB-Seq map generated
using ~3 µg of cortical gDNA. A comparison between data collected using 2 ng or 20 ng gDNA
with ACE-Seq showed high correlation, indicating that ACE-Seq requires comparatively minimal
input DNA (Figure S3-4).
We next performed high-confidence calling of hmC sites in CGs. A comparison of the
detected hmC signal versus the probability that such a signal could be detected at random governs
the statistical calling. The random distribution can be modeled as a binomial distribution (N, p),
where N is the depth of sequencing at that position and p the non-conversion rate given by spikein controls. Using a p-value cut-off of 2.5e-4, we called 798,643 high-confidence hmCG sites in
WT mESCs (Figure 3-4d). By benchmarking ACE-Seq against TKO ESCs, our study offers the
ability to empirically determine, rather than statistically estimate, the false-discovery rate (FDR)
of such a sequencing approach for the first time. Using the same statistical framework we applied
to WT ESCs, 39,684 false positive hmCG sites were detectable in TKO ESCs, resulting in an
FDR of ~5.0% in these samples, identical to that estimated in TAB-Seq (Yu, Hon, Szulwach,
Song, Zhang et al., 2012). In neurons, where hmC is abundant, we can readily call more than 20
million hmC sites, resulting in a calculated FDR of ~0.2%. Although detection of fC and caC is
another theoretical source of false discovery—as A3A discriminates against all ox-mCs
(Schutsky, Nabel et al., 2017)—the abundance of hmC in neurons is at least ~500-fold greater
than fC/caC (Bachman et al., 2014; Bachman et al., 2015), making its contribution to the ACESeq signal negligible. Thus, ACE-Seq permits high-confidence hmC calling at base resolution.

3.3.4

hmC in non-CG contexts is rare
One area of disagreement in prior profiling has centered on the level and significance of

hmC in non-CG (CH) contexts. When subtractive oxBS-Seq or a less-quantitative restriction
enzyme-based method was applied to neuronal samples, hmCH levels were suggested to be
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relatively prevalent (Gross et al., 2015; Mellen et al., 2017). By contrast, TAB-Seq analysis of
mouse cortical DNA indicates that hmC occurs almost exclusively in CG contexts (1.9% of hmC
in CH contexts), with detectable but low levels in ESCs (0.11% in CH) (Lister et al., 2013; Yu,
Hon, Szulwach, Song, Zhang et al., 2012). Using A3A provides an orthogonal approach to these
methods, and, unlike TET in TAB-Seq which has a preference for oxidation of CGs (L. Hu et al.,
2013), has the added strength of being agnostic to the 3’ base (Schutsky, Nabel et al., 2017).
Following the logic applied to hmCG calling, we next performed high-confidence hmCH calling.
Using a p-value cut-off of 5e-8, the FDR for hmC detection in cortical excitatory neurons is
4.0%, obtained from analyzing the sequence-context-matched TET TKO samples. Using this
statistical framework, ACE-Seq confirms that hmC is a rare modification in non-CG contexts,
with only ~2.5% of hmC as hmCH (hmCHH: 427,321 sites; hmCHG: 80,722 sites) in cortical
excitatory neurons (Figure 3-4e). Despite their rarity, at called hmCH sites, the hmC modification
levels are largely comparable to those at hmCG sites (Figure 3-4f). Using a similar analysis in
ESCs, the direct comparison with TET TKO matched controls now allows us to state with
statistical confidence that hmCH is not detectable in ESCs (that is, called hmCH in WT ESCs
does not exceed that in TET TKO), at current sequencing depth.

3.3.5

Genomic distribution of hmCG and mCG in mature excitatory neurons
Having established the hmC landscape in cortical excitatory neurons, we next integrated

our analysis with a neuronal subtype-matched BS-Seq dataset (Camk2a+) (Mo et al., 2015) to
uncover the true composition and genomic patterning of unmodified C, mC, and hmC in murine
cortical excitatory neurons. By subtracting the ACE-Seq signals from those of BS-Seq, we
constructed single-base resolution maps of C, mC, and hmC, revealing that sites that appear fully
‘methylated’ in BS-Seq can vary significantly in terms of hmC and mC distribution (Figure 3-5a,
Figure S3-5). Examining the abundance of modifications at various classes of gene regulatory
elements and genomic features, we found that the levels of hmC at most regulatory elements are
54

significantly lower than those of mC (Figure 3-5b). At promoter-distal enhancers (identified as
open chromatin regions by ATAC-Seq), however, hmC levels are similar to those of mC.
Furthermore, active proximal promoters (H3K4me3-marked transcriptional start sites (TSS) ± 1kb) are depleted in both hmC and mC (Figure 3-5b). This suggests that in a steady-state
population of post-mitotic cells, hmC and mC often coexist within the same class of genomic
feature, and their levels can vary depending upon the genomic context.
To explore the intra-class heterogeneity of modifications in particular regulatory
elements, we analyzed tiled 1-kb genomic bins for C, mC, and hmC distribution and generated
ternary plots that account for all three modification states (Figure 3-5c). Across these bins, a
wide distribution of states can be observed centered on the mode value of ~6% C, ~72% mC, and
~22% hmC. While some genomic features, such as genic regions including exons, track well with
the overall distribution, others show significant deviations (Figure S3-6). For example, 1-kb bins
overlapping with active promoters largely exhibit a homogeneous, hypomodified state, while
those with enhancers display a “long tail” in the ternary plot, reflecting highly heterogeneous,
partially-modified states of hmC and mC (Figure 3-5c). These observations are notable in the
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context of the recent discovery that while the binding of some TFs is diminished by methylation
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Figure 3-5. Genomic distribution of hmC and mC in adult neurons.
(a) Snapshot of base-resolution C (green), mC (red), and hmC (blue) maps near the Neurod6 gene
locus (chr6:55,667,934-55,690,102; genome build: mm10). Only CGs sequenced to depth >=2 are
shown. Gray tracks denote sequencing coverage for each position. (b) The modification levels of
hmCG (blue) and mCG (red) for several classes of genomic elements. The red dashed line denotes
the mCG non-conversion rate in ACE-Seq. Genic features were extracted from the UCSC Refseq
Genes database. Transcriptional activity of promoters/gene bodies and the presence of H3K27me3marked repressive domains reflect experimentally-determined results in Camk2a-positive cortical
excitatory neurons from H3K4me3 and H3K27me3 ChIP-Seq experiments(Lister et al., 2013).
Enhancers (>1 kb from transcriptional start site (TSS)) are determined by ATAC-Seq experiments
in Camk2a-positive cortical excitatory neurons (Lister et al., 2013). (c) Ternary plots show the
levels of C, mC, and hmC within 1 kb bins across the genome (all) or overlapping with
representative genomic elements. (d) Pie chart shows the overlap of called hmCGs with genomic
elements. Each called hmCG site is counted once: the overlap of a genomic element excludes all
previously overlapped sites clockwise starting from active promoter. (e) The relative enrichment
of hmCG (blue) and random sites (gray) at genomic elements (normalized to the coverage of the
element type). ‘Random’ consists of 10 random samplings of genomic elements. Shown on the top
are the ratios (red) between observed and random. (f) Heat-map representation of normalized RNASeq, H3K4me3 (ChIP-Seq), H3K27me3 (ChIP-Seq), hmC (ACE-Seq), mC (derived from BS-Seq
and ACE-Seq), and hmC/mC ratios within 33,136 mouse Refseq genes (gene length >200 bp).
Genes were ranked by their expression levels in Camk2a-positive cortical excitatory neurons.

of their target sequences, other DNA binding proteins display preference for mCG-containing
sequences (Yin et al., 2017). The heterogeneity we observe suggests that TF activity in these
regulatory regions may be similarly influenced by variations in both hmC and mC.
Given the heterogeneity evident in the ternary plots, we next focused on characterizing
specific sites with high hmC levels. While the distribution of hmC in the ~20 million called sites
in neurons varies as a function of genomic features and regulatory elements (Figure 3-5d), we
find that the subset of CGs showing relatively high hmC modification levels (ACE-Seq signal
>60%) is more enriched in transcriptionally-active genic regions (especially introns) and less
enriched within intergenic regions (Figure S3-7). In support of this observation, the relative
enrichment of hmC when normalized to genomic coverage is greater in exons associated with
transcription (observed/random [o/r] = 2.47) and active introns (o/r = 2.57) than in other genomic
regions (Figure 3-5e).
Finally, while DNA methylation within promoter regions and in gene bodies is
implicated in regulation of cell-type-specific transcription, we were interested in whether the
promoter levels of both hmCG and mCG in our excitatory neuron analyses might affect gene
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expression. We therefore rank-ordered the expression level of annotated genes and compared
major histone modifications, as well as our hmC and mC profiles within each annotated gene
body and flanking regions (Figure 3-5f). Consistent with their expression states, actively
transcribed genes, with the expected higher levels of H3K4me3 and lower levels of H3K27me3 at
promoters, show higher intragenic hmC/mC ratios compared with their inactive counterparts.
These observations suggest that TET-mediated oxidation of mC within genic regions may be
positively correlated with gene activity. Overall, our ACE-Seq analysis thus provides a
framework for deconvolution of BS-Seq data with high confidence to parse the roles of hmC and
mC from an otherwise masked signal.

3.4

Discussion
Recent work has demonstrated the potential for exploiting specific DNA-modifying

enzymes to localize genomic features, as exemplified by the use of Tn5 transposase to localize
open chromatin in ATAC-Seq or the monitoring of DNA polymerase kinetics in SMRT
sequencing (Buenrostro et al., 2013; Eid et al., 2009). In the study of DNA cytosine
modifications, while great gains have been made using bisulfite-based approaches, the excessive
degradation of gDNA samples has remained the most significant limitation of chemical
deamination. In this study, we took advantage of the substrate selectivity of DNA deaminases to
devise an enzymatic method for base-resolution localization of hmC. Our base-resolution maps of
hmC generated by ACE-Seq in excitatory neurons correlate strongly with those from prior TABSeq studies on whole brain cortex, giving confidence to both techniques in that the orthogonal
approaches generated similar output. The major advantage of ACE-Seq is that these baseresolution hmC maps were also generated with up to 1000-fold less DNA input. We confirmed
the nondestructive nature of ACE-Seq by generating both long and short amplicons from gDNA
with equal efficiency after exposure of substrate gDNA to our procedure. Given this finding,
ACE-Seq offers the potential to profile DNA from even more rare populations, such as those in
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early development or cell-free DNA samples, when coupled to advances that permit library
construction from limited samples. Additionally, it may now be possible to examine read-lengths
inaccessible to bisulfite-based methods such as multi-kb long enhancer regions.
An added attribute of ACE-Seq is the robustness of discrimination of hmC from C and
mC, which permits high-confidence profiling of hmC. The rate of C conversion is similar to
bisulfite, while mC conversion and hmC non-conversion exceed those of established methods.
The resulting statistical framework permits us to demonstrate confidently that hmC is a rare
modification in non-CG contexts, a question of importance given the purported differences in
hmC interactions with DNA binding partners such as MeCP2 in CG versus non-CG contexts
(Gabel et al., 2015). Merging the base-resolution profiles from BS-Seq and ACE-Seq in purified
excitatory neurons demonstrates the heterogeneity in hmC/mC signals as a function of different
genomic features and regulatory elements, where the functional impact of hmC enrichment and
altered hmC/mC ratios can now be better parsed. At present bisulfite treatment remains useful for
distinguishing C and mC; however, we envision that, building on this precedent, other schemes
integrating APOBEC-mediated deamination could be optimized to discriminate between C and
mC (Figure S3-8). Overall, ACE-Seq expands the repertoire of biotechnological approaches
whereby exploiting nature’s toolbox of DNA-modifying enzymes can be used to great effect for
characterizing and manipulating genomic DNA.
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CHAPTER 4: Future Directions and Concluding Remarks
In summary, this thesis presents both a mechanistic understanding of APOBEC3A’s
activity on modified cytosine substrates as well as exploits these biochemical properties to design,
validate, optimize, and utilize a novel hmC sequencing technology replacing previously-goldstandard bisulfite treatment with nondestructive enzymatic deamination. As a whole, our lab,
along with many collaborators, is interested both in continuing to understand and exploit more
about AID/APOBEC enzymes as well as continue to develop and modify our current ACE-Seq
approach for even broader applicability to previously unanswered questions in epigenetic
regulation. I will focus this chapter on describing ongoing experiments to further develop our
ACE-Seq technology: first in how we are collaborating to optimize ACE-Seq for single-cell
analyses (4.1); second in how we are developing an analogous ACE-Seq approach for direct
readout of mC in genomic DNA (4.2); and finally in how we are characterizing a novel
hyperactive chimeric APOBEC variant which could potentially improve our current ACE-Seq
methodology (4.3). I will conclude this section with remarks on the field as a whole and some
insight into where the field might be headed.

4.1

Optimize single-nucleus ACE-Seq (snACE-Seq) to provide cell type classification,

origin determination of cell-free DNA, and cancer diagnostics4
4.1.1

Introduction
We demonstrated in Chapter 3 that our current ACE-Seq approach can be applied to

1000-fold less input DNA than traditional base-resolution hmC sequencing methods, which will
open the door to previously-inaccessible cell/tissue populations as well as those from early
embryonic timepoints and/or disease states. Due to the nondestructive nature of this technique,
however, we expect that we can theoretically use even less input DNA, even down to the level of

4

This project is currently the proposed thesis work of Emily Fabyanic, a current Ph.D. student in the Wu lab at Penn.
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DNA from a single cell (~5-10 pg). This application is especially important as the field of
epigenetics, by definition, defines differences between cells that contain the same genetic code;
therefore, analyzing bulk samples that average epigenetic data from many cells can only provide
ensemble information and likely obscures important potential findings.

4.1.2

Preliminary results
One limitation in our strategy for direct application in single cells lies in the arena of

library preparation. At present, our current library preparation protocol would not be efficient
enough to generate complex libraries from such a small amount of input DNA. Therefore, we are
currently piloting a new library generation protocol developed as a collaboration between Joe
Ecker and Swift Biosciences for use in single-cell bisulfite sequencing (Luo et al., 2017). The
major difference is the initial use of a random priming step before their patented Adaptase
reaction that should help to increase the complexity of the library. Initial attempts at using this
library preparation protocol have proven successful for both phage and mammalian DNA with 0.5
ng gDNA input (~50-100 cells).
Another important limitation for optimizing our traditional workflow for snACE-Seq is
our ability to shear genomic DNA from single cells. In our traditional workflow, we have been
able to purify genomic DNA from a bulk cellular population, shear using sonication, and then
input this sheared DNA into our ACE-Seq reactions. However, such limited DNA input from
single cells prevents purification and mechanical shearing without significant loss of DNA. Our
first attempt to generate fragmented DNA from single cells actually relies on bisulfite treatment,
which, as discussed previously, is known to fragment DNA. This treatment can be directly
applied to lysed single cells using the Zymo EZ-96 DNA Methylation Direct Kit. Initial attempts
at using bisulfite treatment followed by ACE-Seq to localize hmC has been somewhat successful,
in that DNA does appear to be fragmented and we are able to achieve both robust bisulfite
conversion of Cs and A3A conversion of mCs. Importantly, one unknown factor going into this
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approach was whether the CMS adduct generated by the bisulfite reaction with hmC would be
sufficient to prevent deamination of hmC by A3A in lieu of glucosylation. Indeed, we were able
to achieve protection of hmC at levels similarly high as our traditional ACE-Seq workflow
utilizing glucosylation via βGT (Figure 4-1).
Currently, we are utilizing the approaches outlined above to provide a framework for
optimizing ACE-Seq conditions for snACE-Seq. For example, we are currently testing whether

Figure 4-1. Bisulfite conversion of hmC to CMS upon bisulfite treatment protects from A3Amediated deamination

we can possibly utilize less A3A in the reactions given that (1) we have significantly less DNA to
convert, (2) bisulfite will have already converted all Cs, so A3A only needs to convert mCs
efficiently, and (3) we will need to perform many hundreds of reactions at once on single nuclei
in order to generate a robust initial data set, and we are currently limited by the amount of A3A
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generated by each protein preparation. Results to this end have been complicated by the use of
many different preps, though it does seem possible that we could decrease the amount of A3A in
each reaction from 5 uM to at least 2 uM while maintaining similarly high levels of conversion
(Fig 4-2). This is a promising first step, as it will allow us to, in effect, more than double the
amount of reactions we can perform with a single preparation of enzyme.

Figure 4-2. Conversion efficiencies of ACE-Seq on lambda
(C/mC) and T4-hmC spike-in controls with 2 uM enzyme

4.1.3

Next steps
This project is still very much in its preliminary stages, so there are many different

approaches we are currently trying out for the snACE-Seq adaptation. For example, we are not
planning on utilizing bisulfite as our fragmentation step in the long term, as it comes with many
of the caveats discussed previously (Tanaka and Okamoto, 2007), the most notable of which is its
destructive nature which limits the complexity of any resulting library for subsequent Illumina
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sequencing. One potential option we will explore is the use of an enzymatic “fragmentase,” which
is now commercially available from New England Biolabs. Use of this enzyme will continue to
improve our nondestructive method (as the enzyme should fragment the genome but not produce
abasic sites or other destructive effects), and the size of average fragments can be controlled
through time of incubation with the enzyme. While this requires much initial optimization both to
achieve the right fragment sizes and to determine optimal conditions so as to move from
fragmentation to BGT/A3A treatment without comprising the efficiency of the latter steps. We
are also pursuing another approach previously applied to single-cell Hi-C, where barcodes and
Tn5 transposase are directly applied to permeabilized nuclei to simultaneously barcode and
fragment the gDNA (Ramani et al., 2017). As discussed below in Section 4.3, we are also
interested in characterizing and optimizing a hyperactive chimeric APOBEC variant for use in
both traditional ACE-Seq and possibly in snACE-Seq, which could even further lessen the
amount of enzyme required for complete conversion in each step.
Once optimal conditions are achieved for fragmentation, hmC protection, and C/mC
conversion, we will perform a pilot experiment on 384 individual sorted nuclei from wildtype
murine cortical neurons from different stages of embryonic development using a nuclear isolation
technique developed in the Wu and Zhou labs (P. Hu et al., 2017). Initially, we will use snACESeq in conjunction with single-nucleus Drop-Seq (snDrop-Seq), a method for massively parallel
RNA sequencing from sorted nuclei developed in Hao Wu’s lab. Using both of these methods
together, we aim to address the biological question of how intragenic hmCG levels correlate to
gene expression on a cell-by-cell basis, and whether we can use hmC localization data from
snACE-Seq to classify distinct neuronal subtypes, potentially those previously unidentified, by
combining both epigenetic and transcriptional information. There are many other potential
applications for this method as well, especially as base resolution hmC signals have never been
observed on a cell-by-cell basis, so the questions that remain to be answered are seemingly
endless. With snACE-Seq, we are poised to answer mechanistic questions regarding the
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correlation between single cell hmC levels and localization, either in certain genomic elements or
in specific genes of interest, and provide functional evidence for certain phenomena we observe
in single cells.

4.2

Develop mC-ACE-Seq for nondestructive, direct readout of genomic mC utilizing a

fully-enzymatic workflow5
4.2.1

Introduction
When we initially conceived the idea of ACE-Seq – i.e. using APOBECs for

deamination/conversion instead of bisulfite – we envisioned that the protocol could be optimized
either for mC detection or hmC detection (Fig XX). As explained in Chapter 3, we first decided
to focus on hmC detection, because 1) our strategy for hmC detection requires fewer steps that
would need to go to completion than our proposed mC detection strategy, and 2) these steps are
catalyzed by enzymes that either we or others have extensively characterized (notably, βglucosyltransferase and APOBEC3A). We also determined that there could be a greater need for
hmC characterization, as single-cell bisulfite technologies for mC detection, though limited in
their utility, had already been developed, whereas no similar optimization for single-cell
applications had been successfully developed and employed for TAB-Seq, oxBS-Seq, or any
other base-resolution hmC detection strategy.
As we have now developed hmC-ACE-Seq successfully, the next logical goal is to use
what we have learned about A3A and about the design, optimization, and validation of
sequencing technologies to develop mC-ACE-Seq – an analogous base-resolution method for the
detection of genomic mCs utilizing APOBECs. From Figure S3-8, our original idea was to build
off the TAB-Seq workflow, utilizing Tet to oxidize all modified cytosines (mC, hmC, fC, and
caC) up to caC, which would be resistant to APOBEC3A-catalyzed deamination according to our

5

This project is currently the thesis work of Tong Wang, an MD/PhD student in the Kohli Lab.
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kinetic characterization (Table 2-1); therefore, the only bases that would be deaminated and read
as Ts would be unmodified Cs, and all modified Cs would be protected from deamination and
read together as Cs. We envisioned a few issues with our approach. First, this method relies on
complete oxidation by Tet, which has been known to be difficult to achieve robustly. Secondly,
and perhaps more importantly, this method would read out all modified Cs together instead of mC
specifically, apart from the ox-mCs. This is a current drawback of standard bisulfite sequencing,
as mCs and hmCs are read out together. As such, this method could only be used to map mC
through bioinformatic subtraction from an independent hmC-ACE-Seq experiment. Therefore, we
aimed to design a strategy in which we could achieve direct readout of mC apart from the other
ox-mCs, and therefore refine our knowledge of how the locations and prevalence of mC vary
across different tissues, embryonic timepoints, and disease states.

4.2.2

Preliminary results
Given our goal of achieving direct readout of mC with limited DNA input, we abandoned

the idea of Tet oxidation and instead considered properties of APOBEC3A that we could exploit
for this purpose. We noted from our kinetic characterization (Table 2-1) that A3A employs a
steric mode of discrimination against modified cytosines, in which larger substituents prevent
catalysis and smaller substituents are more efficiently deaminated. We therefore postulated that if
we could modify unmodified cytosine in vitro with a bulky group at the 5-position as a first step
to this method (along with βGT protection of hmC as in traditional hmC-ACE-Seq), we could
prevent its deamination and solely focus on detecting mC (Fig 4-3). The enzymes that are known
to modify this 5-position in vivo are DNA methyltransferases, which canonically transfer the
methyl group from S-Adenosylmethionine (SAM) to the 5-position of cytosine to form

67

methylcytosine. It has been previously reported that certain point mutants of the bacterial
methyltransferase, M.SssI, can potentially utilize synthetic alkyl donors to transfer larger alkyl
groups to cytosine (Kriukiene et al., 2013). We therefore hypothesized that if we could

Figure 4-3. Potential workflow for mC-ACE-Seq for direct readout of mC
Unlike hmC-ACE-Seq, unmodified cytosine must be protected from deamination. We
propose the use of a mutant DNA methyltransferase that can transfer bulky alkyl groups
from SAM analogs to the 5-position of unmodified cytosines. Therefore, after treatment
with BGT and A3A, only mC should be deaminated and read as a T in sequencing.

successfully generate and validate mutant methyltransferases that could efficiently modify
cytosine with an alkyl group to cytosine large enough to prevent A3A deamination, we could
utilize this approach for mC-ACE-Seq.
To this end, we have taken a parallel approach of (1) characterizing and/or evolving
methyltransferase mutants that could accept larger alkyl groups, and (2) assaying the ability of
A3A to deaminate larger alkyl groups. Our goal is to pursue both of these strategies in tandem in
order to find the ideal mutant methyltransferase and synthetic alkyl donor for mC-ACE-Seq.
Towards the first goal, we have successfully cloned the Q142A/N370A mutant from
literature that has been shown to accept and transfer larger alkyl groups like Ado-6-amine, a 6
carbon alkyl chain containing a terminal primary amine (Kriukiene et al., 2013). We are currently
optimizing strategies to express and purify this enzyme from bacteria without incurring the
toxicity of modifying cytosines in the bacterial genome during expression.
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Towards the second goal, we first decided to test the ability of A3A to deaminate
ethylcytosine (eC), as it is larger than methylcytosine and has a similar size to hmC, which is
largely resistant to A3A-mediated deamination. We used the LATE-PCR strategy employed in
Chapter 2 (Fig S2-1B) with deoxy-ethylcytosine-triphosphate (deCTP) in the dNTP pool in order
to generate long, single-stranded substrates with many eCs in various sequence contexts
throughout the ssDNA substrate. When we incubated this substrate with A3A and analyzed the
TA-clones of the resulting products, we noted significant eC deamination across each clone
(>60%), mostly occurring in the 5’-TC preferred sequence context of A3A (Fig 4-4). This result

Figure 4-4. Deamination of ethylcytosine by APOBEC3A
Each line of sequencing is representative of a Sanger sequencing read from A3A
treatment of DNA containing either unmodified C, mC, or ethylcytosine (eC)
compared to the parent sequence (not deaminated).

was not entirely unexpected as hmC is also known to deaminate somewhat under the “driving”
A3A conditions utilized above. Therefore, we concluded that this analog would not be ideal for
use in mC-ACE-Seq, and that longer alkyl chains should be pursued.

4.2.3

Next steps
From the previous experiment, we hypothesized that A3A’s relatively-efficient

deamination activity on eC was likely due to the rotational flexibility of the ethyl group that
would allow it to adopt more favorable conformations for fitting into the active site for
subsequent deamination. Therefore, we postulated that more rotationally-constrained alkyl groups
(e.g. those with double or triple bonds) might hinder deamination while still being small enough
to be efficiently transferred by a methyltransferase. In addition to added rigidity, double or triple
bonds at the beta- and gamma-carbons were shown to promote alkylation by the Q142A/N370A
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mutant M.SssI as they create a pi system that stabilizes the SN2 intermediate between the cytosine
nucleophile and the SAM-analog electrophile (Kriukiene et al., 2013). Therefore, the SAM
analogs we are currently considering for use in mC-ACE-Seq are summarized in Figure 4-5.
Many of these analogs are currently being synthesized in our lab as modified dCTPs and will
soon be tested as substrates for A3A using a similar LATE-PCR-based assay as above.
In terms of generating and characterizing methyltransferase mutants, we first aim to

Figure 4-5. SAM analogs to be considered for use in mC-ACE-Seq
As mC is known to be near 100% deaminated, and we observed 65% eC deamination, we
propose the use of bulkier alkyl groups that can be easily synthesized as dNTPs and assayed
using LATE-PCR.

finish our characterization of the M.SssI Q142A/N370A mutant from literature after optimizing
its expression and purification. An alternate strategy we have considered is to preliminarily screen
this and any other methyltransferase mutants using partially-purified protein generated using an in
vitro transcription and translation protocol that would successfully remove the necessity of nontoxicity in bacterial systems. Any promising candidates from this approach could then be scaled
up for expression and purification. We are also cognizant of the fact that previously-identified
mutants might not perfectly fit our goal of complete labeling/protection of all genomic Cs.
Therefore, we plan to use saturation mutagenesis to generate all possible amino acid substitutions
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at the two positions identified from the literature (Q142 and N370) and possibly other positions in
M.SssI that we rationally choose from investigating the structure of a related methyltransferase
(Wojciechowski et al., 2013). This approach has been successfully utilized by our lab previously
to generate mutants of human TET2 that only catalyze one oxidation event (mC to hmC) instead
of the three oxidation events catalyzed by the wild-type enzyme (generating hmC, fC, and caC)
(M. Y. Liu et al., 2017).
Once we determine the ideal chemical moiety that can both be efficiently transferred by a
mutant methyltransferase and can prevent deamination by A3A, we will validate our approach in
a manner analogous to our validation of hmC-ACE-Seq. As controls to assess the efficiency of
each of the steps in mC-ACE-Seq, we will include three spike-in control genomes of known
composition: 1) methylated lambda phage (as in hmC-ACE-Seq) to assess the false negative rate
resulting from inefficient A3A deamination of mC; 2) a CpG-alkylated phage to assess the false
positive rate resulting from inefficient C protection by our mutant methyltransferase and/or its
deamination by A3A; and 3) the T4-hmC phage (as in hmC-ACE-Seq) to also assess the false
positive rate resulting from inefficient protection of hmC by glucosylation.
As a novel application of this technique, we plan to utilize mC-ACE-Seq to identify mCs
at base resolution in circulating cell-free DNA (cfDNA) samples for oncogenic tissue-of-origin
analysis as well as early cancer diagnosis. In brief, cfDNA is known to be present in circulating
blood samples and likely comes from cells that have previously undergone apoptosis or necrosis.
One study used publicly available whole genome bisulfite sequencing data in order to identify
regions that were differentially methylated between 14 tissue types, and then generated an
algorithm utilizing over 6,000 differentially methylated regions in order to accurately predict the
relative contributions of cfDNA in the blood from various tissues of origin (K. Sun et al., 2015).
Therefore, we aim to use mC-ACE-Seq to sequence cfDNA of healthy and diseased patients in
order to see if mC-ACE-Seq can predict the tissue of origin of patients with biopsy-confirmed
cancers.
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4.3

Characterization and development of a novel chimeric APOBEC for use in ACE-

Seq or other biotechnological applications6
4.3.1

Introduction
One of the drawbacks to our current ACE-Seq methodology is that we have to use a very

high concentration of A3A in order to deaminate all Cs and mCs regardless of sequence context.
In many ways, this is not a significant deficit as A3A is comparatively easy to express and purify
at high concentrations. However, if we were able to optimize our method to use less enzyme, this
could make the methodology easier to translate into a commercial kit and would lessen the
cost/effort of many expression/purification cycles when more enzyme is needed.
In a side project that was not discussed at length in this thesis document, I generated a
hyperactive APOBEC mutant in a somewhat-unexpected manner. For this project, I was
exploring the biochemical and cellular differences between APOBEC3A and one of its closelyrelated family members, APOBEC3B, as both of these APOBECs have been postulated to be
involved in the APOBEC cancer signature discussed in Section 1.1.2.1. Interestingly, the catalytic
domains of these enzymes are ~90 % identical: all catalytic and HRL residues are conserved and
only 15 amino acids differ between the two, localizing to either the N- or C-terminal ends of the
catalytic domains; however, even with this high level of conservation, there is a drastic difference
in activity in vitro (Siriwardena et al., 2015). The main hypothesis for this difference in activity is
the predominant molecular difference between the two enzymes: the presence of a duplicated, yet
inactive, deaminase domain at the N terminus of A3B (denoted A3BNTD here), leading to a
double-domain deaminase as opposed to A3A, which only contains a single deaminase domain.
In an attempt to ask whether the presence of A3BNTD dampens the activity of the C-terminal,
catalytically-active domain, we generated many different constructs of both A3A and A3B. For

6

Preliminary data for this section was generated in part by me, in part by Nikita Agarwal, a previous undergraduate
student in the Kohli Lab, and in part by Craig Gambogi, a previous rotation student in the Kohli Lab.
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Figure 4-6. Toxicity of colonies as a proxy for hypermutator activity in A3BNTD-A3A
While all constructs allow non-expressing cells (NEB Turbo) to grow, A3BNTD-A3A, when transformed
into expression cell lines (BL21(DE3) with trigger factor), causes a lack of colony growth. We
hypothesize that this is due to high levels of toxicity from hypermutator activity.

the purposes of this discussion, the most interesting observation occurred when we created a
chimeric APOBEC mutant that fused A3BNTD to the N terminus of APOBEC3A to generate the
A3BNTD-A3A fusion protein (Fig 4-6). When we transformed the plasmid containing this
construct into BL21(DE3) E. coli expression cell lines, we saw no colony growth. As we
generally see very small colonies when transforming A3A into the same cell line due to apparent
toxicity from leaky expression, we hypothesized that A3BNTD-A3A could also be toxic to the E.
coli, possibly due to increased catalytic activity and subsequent mutation of the bacterial genome.
Therefore, we aimed to devise a strategy for expression and purification of A3BNTD-A3A to test
our hypothesis of increased activity, with the hopes of developing a robust expression and
purification strategy so that purified protein could be both fully characterized and possibly
utilized in subsequent optimizations of ACE-Seq.
73

4.3.2

Preliminary results
We first aimed to devise a strategy to test our hypothesis that the observed toxicity of

A3BNTD-A3A was due to high levels of mutagenic activity. As bacterial growth was
compromised, we sought to use an in vitro transcription/translation (IVTT) protocol to generate
polypeptide from our plasmid without the need for bacteria. After incubation with the necessary
transcription and translation components, crude sample was incubated with single-stranded DNA
substrate, which was then subjected to a UDG-coupled deaminase assay. Even though protein
was not expressed at high enough levels to detect via Coomassie stain, we observed robust
deaminase activity compared to A3A (Figure 4-7). Therefore, we postulated that low levels of

Figure 4-7. Activity assay of A3BNTD-A3A expressed from in vitro transcription/translation
In this UDG-based assay, uracil-containing oligos are cleaved and run faster (lower band) while cytosinecontaining oligos are uncleaved and run slower (higher band). While protein expressed from the “control
template” and also the catalytic mutant of A3BNTD-A3A showed no deaminase activity, we observed robust
deaminase activity from both A3A and A3BNTD-A3A.

A3BNTD-A3A were being expressed, yet were enough to show robust deaminase activity. Even
though this method produced very low amounts of protein, we were encouraged by the initial
activity assay showing robust activity and decided to characterize this activity further. To that
end, we used a small-scale amylose purification, utilizing the maltose binding protein (MBP) tag
at the N terminus of our construct, to partially purify A3BNTD-A3A. We then had just enough
protein to perform an initial Michaelis-Menten activity assay. Our preliminary data suggests that

74

A3BNTD-A3A has a lower KM than A3A alone (Figure 4-8). This property could suggest
processivity – that the protein can bind to DNA and catalyze many successive deaminations
without dissociating from the DNA substrate itself – or could suggest that A3BNTD-A3A has a

Figure 4-8. Michaelis-Menten kinetics of A3BNTD-A3A compared to A3A
Using limiting enzyme and titrating higher substrate concentrations, we estimated a KM for
A3BNTD-A3A that was approximately 5-fold lower than that of A3A.

higher binding affinity to DNA. However, future experiments will need to be performed to test
this hypothesis. Due to the fact that we preliminarily observed this interesting shift in kinetic
parameters from A3A to A3BNTD-A3A, we decided to pursue alternative expression methods for
generating higher amounts of protein so that we could perform more thorough kinetic
characterization.
We initially tried a plethora of cell lines and/or plasmids that were designed/engineered
to employ very stringent control of expression to prevent potential toxicity from leaky expression.
In all of these cases, we either observed no colony growth, or we found that the few colonies that
grew had accrued mutations in the A3A expression plasmid that resulted in truncated or inactive
versions of A3A. From these observations, we postulated that even a single “leaky” expressed
copy of A3BNTD-A3A could have dire consequences for bacterial cell survival. Therefore, we
needed to devise a system in which there would be no leaky expression of A3BNTD-A3A prior to
induction of protein expression.

75

We found initial success in utilizing a “degron” approach. A short, eleven amino acid
sequence (called an “SsrA” tag) was added to the 3’ end of our A3BNTD-A3A expression
construct before the stop codon so it would be translated at the C-terminal end of A3BNTD-A3A.
This tag is commonly recognized by the ClpXP protease in bacteria which facilitates the process
of degradation of the associated protein (Keiler et al., 1996; Gottesman et al., 1998). We
hypothesized that by adding this tag to our protein, we could degrade, and therefore prevent
toxicity of, any proteins that were expressed prior to induction; after induction, however, we
hypothesized that the degradation machinery would be overwhelmed and would allow our protein
to be expressed at high quantities. Indeed, we placed our construct (containing the C-terminal
SsrA tag) under the control of a tetracycline promoter and transformed into expression cell lines.
Whereas before we were never able to see any colonies (unless the construct had mutated and
become inactive), we saw many small colonies. When we grew these in liquid culture at a larger
volume and induced, we were able to see our protein of interest on a Coomassie-stained SDSPAGE gel. While we struggled to purify this protein to homogeneity, we were able to do a
qualitative deamination assay on the partially-purified elution fractions from this prep, and were
able to observe robust deaminase activity. Therefore, we hypothesize that, utilizing this degron
strategy, we should be able to scale up this protein preparation and obtain enough protein to be
able to perform thorough biochemical characterization. From this experiment, we hope both to
understand the kinetic role of the inactive N-terminal domain of A3B as well as potentially be
able to leverage this hyperactive protein for use in ACE-Seq, CRISPR-dCas9 fusions for editing,
or other biotechnological applications.

4.3.3

Next steps
While we are very encouraged by our preliminary results in characterizing this chimeric

fusion deaminase, there are still many obstacles that need to be overcome in order to generate
high-yield, highly-pure enzyme, both for characterization and for commercial use. First, much of
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the expressed protein in our current protocol is insoluble, so pursuing non-catalytic mutations in
the A3BNTD that increase solubility could aid in our ability to produce more soluble protein,
possibly building off the precedent of mutating AID to increase solubility and prevent
oligomerization (Qiao et al., 2017). We have also considered engineering small molecule-induced
dimerization domains on each half of the fusion, which would allow us to express them separately
(to minimize toxicity) and then trigger their interaction with a small molecule; however one
caveat to this approach is that we do not know whether the hyperactivity we see can be
recapitulated in trans, or whether the proteins have to be genetically fused. Next, we want to
develop a purification strategy that will allow us to purify this protein to homogeneity for
biochemical and biophysical characterization. At present, our current amylose purification
strategy allows only partial purification as many lower molecular weight bands also elute with
our protein of interest. In previous experiments with A3A, we have generated highly-purified
protein utilizing cobalt resin as a histidine-tag-immobilization strategy. However, our initial
degron construct added the degron at the C terminus of the His tag, occluding its ability to
successfully bind the cobalt resin. Therefore, we are currently generating an alternative construct
where the histidine tag is moved to the N terminus (creating an 8xHis-MBP-A3BNTD-A3A-SsrA
construct) to allow greater flexibility of the 8xHis tag and hopefully increase our yield and purity
after cobalt purification.
Once we are able to produce purified protein in large quantities, we will perform robust
Michaelis-Menten characterization of A3BNTD-A3A in comparison to WT A3A, WT A3B, and
catalytically inactive A3BNTD-A3A(E72A). We hypothesize that our preliminary data will hold
true, and that A3BNTD-A3A will have a similar kcat value as A3A but a lower KM. We will further
test our hypotheses regarding tighter binding/processivity by using fluorescence polarization (FP)
to calculate a KD value for each of these constructs. To test whether the toxicity we see in
bacteria translates to mammalian systems, we can also move this A3BNTD-A3A construct into a
plasmid for mammalian cell expression, transfect mammalian cells, and not only observe
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phenotypic changes, but also determine its subcellular localization and quantify DNA damage by
gamma-H2AX staining or TUNEL assays. Building on experiments discussed in Section 1.1.2.1,
we hope these analyses will give insight into the mechanism of APOBEC-induced oncogenic
mutations and potentially fuel routes for drug design to inactivate the APOBEC(s) that cause
hypermutation in cancer patients.
Finally, we are very interested in developing A3BNTD-A3A as a new tool for
biotechnological applications. Notably, using less, yet more active, enzyme in the ACE-Seq
protocol would be time- and cost efficient for any lab or company generating large quantities of
the protein for ACE-Seq but would still maintain the high quality of the method. Also, while
whole-genome ACE-Seq has remarkably high conversion rates, initial attempts at using ACE-Seq
on unsheared mammalian DNA for locus-specific analyses has suffered from a higher rate of
certain strands that remain fully unconverted, likely due to poor denaturation or efficient
reannealing of the DNA strands before A3A could successfully deaminate. If A3BNTD-A3A is
processive, it might lessen the impact of reannealing and allow for successful deamination of full
strands of DNA without the need for shearing or other amendments to the snap cooling
procedure. This hyperactive A3BNTD-A3A protein could also be fused to dCas9 using a similar
strategy as discussed in Section 1.1.3 for other deaminases which could increase the efficiency of
targeted editing and overcome many of the current issues with this editing approach. However, it
is unclear whether this fusion would also result in higher off-target activity, or any sort of toxicity
in living systems. Overall, we propose that this hyperactive chimeric A3BNTD-A3A deaminase
could be utilized for a variety of both biotechnological applications and as a mutagenesis tool in
molecular biology.

4.4

Concluding Remarks
It has been a huge pleasure to be part of a field that has been ever-evolving since the

discovery of the first APOBEC enzyme 25 years ago. There is never a dull moment when
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working to understand an enzyme family that is so mysterious and counterintuitive, and yet also
so popular: Though we know so little about their regulation and specific physiological and
pathological functionalities, they remain such an attractive target for biotechnology and lovers of
enzyme mechanism and natural selection. And as if this realm of purposeful mutation wasn’t
stimulating enough, I also got to take a voyage into the rapidly expanding new field of
epigenetics, and in a way not only to learn about DNA bases I didn’t know existed before this
thesis work was started but to actually contribute a powerful methodology from the hands of an
epigenetics novice. Truly, I could not have asked for a better environment to learn, grow, be
exposed to new and exciting scientific paradigms, and ask new questions as a young scientist.
I am very excited to see how this field evolves in even just the next decade. I highly
anticipate the next frontier of specifically adding or subtracting single modifications or editing
events and being able to ask physiological questions in important cell or tissue types, and possibly
even on a single-cell level. To this end, I await the optimization and functional use of genomic
modification/editing tools employing the enzymes discussed in Section 1.1.3 that will be
powerful both for basic science and for clinical applications as well. I am sure it will be paradigm
shifting in many ways to know how epigenetic marks directly affect the identity and purpose of
single cells in the body. Finally, I am confident that ACE-Seq and any iterations or optimizations
thereof will be able to answer many more fundamental biological questions than could possibly
be addressed in this thesis, yet will hopefully be asked and addressed by ours and other labs
around the world.
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APPENDIX
Supplementary Figures and Tables for Chapter 2

Table S2-1. Sequences and mass confirmation of substrate and product control oligonucleotides
(A) Oligonucleotides were synthesized using standard phosphoramidite chemistry including a 3’ FAM moiety. The masses of
these oligonucleotides were confirmed using MALDI-TOF mass spectrometry. (B) Oligonucleotides used for mC sequence
preference studies were purchased from IDT, and mass was confirmed using MALDI-TOF mass spectrometry. A DNA standard
(MW=11598.2 Da) was purchased from IFT and read on MALDI as 11601 Da, indicative of mass range accuracy. (C) Complement
oligonucleotides used in SwaI or TDG-based assays were purchased from IDT and the reported masses are from ESI-MS analysis
performed by IDT.
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Figure S2-1. SwaI selectivity for modified uracils (xU) and not modified cytosines ( xC)
(A) SwaI has no cleavage activity on xC-containing substrates, and effectively cleaves xU-containing DNA. (B)
Phosphoramidites for 5-formyluracil (fU) and 5-carboxyluracil (caU) were not commercially available to synthesize
product controls with standard phosphoramidite chemistry. Therefore, fU- and caU-containing oligos were synthesized
chemoenzymatically. A 5’-FAM labeled oligonucleotide S18 was annealed to a 21-mer complement and extended with
dATP and either TTP, 5-formyl-dUTP, or 5-carboxyl-dUTP and Klenow(exo-) polymerase. The extended S21 strand
was then annealed to excess S35-C-Comp and again subjected to primer extension to generate the 35-mer product control
containing T, fU, or caU. (C) The purified oligonucleotides from each chemoenzymatic step are shown. While the
corresponding xC substrates were not cleaved (see (A)), SwaI is able to cleave the oligonucleotides containing T, fU, and
caU. Notably, a 5’-label was required for monitoring steps in the chemoenzymatic synthesis. The SwaI cleavage products
for fU and caU controls therefore are associated with 5’-labeled 19-mers (P19) rather than 3’-labeled 16-mers (P16) for
all other product controls and for the deaminated substates, which all have 3’-FAM labels. For clarity, the fU and caU
product controls are not shown in Fig 2-2 to avoid confusion between the P16 resulting from cleavage of deaminated fC
and caC.
The recently reported structures of SwaI in complex with DNA (PDB 5TGX, 5TH3, Reference 44) provide some insight
into the reasons why SwaI is well suited to our assay. In the structures, the two central base pairs of the restriction site
(5’–ATTTAAAT–3’) are highly distorted and lose Watson-Crick base pairing with the opposite strand; instead, the A
bases on opposite strands stack with each other and the T bases are rotated away from the helix. These rotated T bases
make specific contacts with SwaI via their Watson-Crick face, while there is space in the vicinity of the 5-position methyl
group, with the closest residue located ~3.8 Å away. This latter observation provides a rationale for how the enzyme is
permissive to the identity of our variously modified uracil analogs.
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Figure S2-2. Conditions for kinetic experiments with A3A and caU detection limit
(A) 500 nM radiolabeled S35-C substrate was incubated with 100 pM A3A at 37 ºC. Serial timepoints were taken and
terminated by heat inactivation. The samples were subjected to the UDG-based assay and product formation was
quantified. Product formation was linear to at least 45 min. (B) Conditions used to for determination of deamination
kinetics in Table 1 (main text). Enzyme and time conditions were chosen with target of <20% substrate conversion to
product. (C) Limit of detection for caU. Known mixtures of S35 oligonucleotides with caC or caU were generated, treated
with SwaI, and the amount of cleavage product was quantified. Shown is the plot of known caU in the sample versus
calculated caU from the SwaI digest. This experiment was done in four independent replicates and the linear regression
was calculated by GraphPad Prism software. Although caU cleavage is not complete, the detected product is linear from
5 to 100%, with detectable cleavage when the product is as low as 5% of the sample. The kinetic assays were performed
with 2 µM substrate, providing a limit of detection of 100 nM. Under the assay conditions tested this translates to a kcat
detection limit of 0.002 min-1 for A3A acting on caC-containing DNA.
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Figure S2-3. Curves from steady-state kinetic analyses
(A) Rate versus substrate concentration curves for the substrates S35-C, S35-mC, S35-flC, and S35-brC with
corresponding kinetic constants shown. Data were fit with Michaelis-Menten parameters using GraphPad Prism software.
Error bars indicate standard deviation from three independent replicates. (B) Deamination product versus enzyme
concentration curves for S35-iC, S35-fC, and S35-hmC substrates performed at saturating substrate concentrations.
Experiments were performed in duplicate (S35-iC) or triplicate (S35-hmC, S35-fC) and fit with linear regression on
GraphPad Prism software after appropriate background subtraction from control experiments without A3A treatment.
Error bars indicate range for S35-iC experiments and standard deviation from replicate experiments for all other
substrates.
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Figure S2-4. Design and synthesis of long ssDNA substrates
(A) 636mer DNA substrate designed to analyze C and mC deamination. Primer touchdown locations are shown in red
(exterior primers; F1 and R1) and blue (interior primers; F2 and R2). (B) Table of sequence contexts and their occurrences
in the 636mer substrate. The sequence contains 183 cytosine bases with all NNC triplets represented (range 6-22 times).
(C) Schematic of ssDNA 636mer synthesis. LATE-PCR is performed with dATP, dGTP, dTTP and either dCTP or 5methyl-dCTP. A limiting amount of the phosphorylated primer R1 is used, giving rise to both double-stranded and singlestranded species. The phosphorylated strand is degraded by lambda exonuclease to enrich for the ssDNA substrate. (D)
A 2% agarose gel stained with Sybr-Gold, depicting double-stranded and single-stranded species resulting from LATEPCR and subsequent lambda exonuclease treatment. The ssDNA is gel purified from the lambda exonuclease treated
sample and used for further studies.
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Figure S2-5. The effect of downstream (+1) position on C and mC deamination
The deamination experiments on long ssDNA substrates described in Figure 3 were analyzed for the impact of the
downstream (+1) position on C and mC deamination. Plotted are the fractions of deaminated bases in each context as a
function of A3A concentration, shown in identical format to the -2 and -1 position analysis in Figure 3. The EC50 is the
enzyme concentration to achieve 50% deamination of C or mC bases in each condition and was calculated by fitting each
curve to a hyperbolic function. The fold discrimination is the ratio of EC50 for a given base, relative to that of A, the
most favored +1 base for C deamination.

Figure S2-6. The combined effect of upstream sequence context on C and mC deamination
For the 636-mer ssDNA substrate deamination experiments shown in Figure 3, the cytosine bases in a preferred TTC/mC,
intermediate TGC/mC, or disfavored GAC/mC context were analyzed separately for deamination by A3A. Plotted is the
fraction of deaminated bases in each condition as a function of A3A concentration. The values for EC50, the enzyme
concentration to achieve 50% deamination of all C or mC bases in a particular context, are reported, along with the ratio
of C:mC deamination for each sequence context.
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Figure S2-7. Kinetics of C deamination in varied sequence contexts
Oligonucleotides containing a single cytosine in preferred (TTC), intermediate (TGC), or disfavored (GAC) sequence
context were reacted with A3A under steady-state conditions appropriate for each substrate (see Material and Methods).
Deamination was analyzed by a UDG-coupled assay and fit to Michaelis-Menten parameters. While the overall kcat
values determined by the UDG-coupled assay are lower than those determined by the TDG-coupled assay (Figure 4), the
trends are consistent. Importantly, differences in reactivity are predominantly attributable to changes in kcat. While the
determined kcat values span a ~25-fold range across the various sequence contexts, the KM values differ by only 2.2fold.

86

Supplementary Figures and Tables for Chapter 3

Figure S3-1. Chemical and/or enzymatic deamination across various sequencing
methods to localize modified cytosines
(a) Upon treatment with bisulfite under acidic conditions and at elevated temperatures, unmodified
cytosine becomes sulfonated at the 6 position, which facilitates its hydrolytic deamination. Moving to
alkaline conditions promotes desulfonation to yield uracil. In contrast, APOBEC3A catalyzes
enzymatic hydrolytic deamination under physiological temperatures and pHs. (b) Workflows of
various deamination-based sequencing methods to localize modified cytosines. Traditional bisulfite
sequencing (BS-Seq) localizes mC and hmC together after deamination of unmodified C. TET-assisted
bisulfite sequencing (TAB-Seq) changes reactivities to specifically localize hmC by first protecting
hmCs with a glucose moiety and then oxidizing mCs with TET to form 5-formyl or 5carboxylcytosine, which will be read as T following bisulfite conversion and sequencing. Oxidative
bisulfite sequencing (oxBS-Seq) directly localizes mCs by oxidizing hmC with potassium perruthenate
before bisulfite treatment. When used in conjunction with standard bisulfite sequencing, hmC can be
indirectly localized through subtraction of the oxBS signal from that of BS-Seq. Finally, APOBECCoupled Epigenetic Sequencing (ACE-Seq) does not rely on bisulfite, and instead utilizes enzymatic
deamination of C and mC by APOBEC3A after protecting hmC with a glucose moiety. The sequencing
readout therefore is comparable to TAB-Seq without the need for the destructive bisulfite treatment.
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Figure S3-2. Phenotypic validation of modifications in phage DNA
(a) Validation of T4 mutant phenotypes by restriction digest. AluI cleaves only unmodified
cytosine-containing DNA, while MspJI selectively cleaves hmC-containing DNA.
Exogenous treatment of T4-hmC with a glucosyltransferase also causes a mass shift to
generate a band the same size as T4-ghmC. The gels are adapted from Bryson, et al. mBio,
2015 (PMID: 26081634) with permission from mBio and the corresponding authors;
specifically, only panel A of the original figure was used, and the labels were altered slightly
to align with nomenclature used in this article. (b) Validation of CG methylation of lambda
phage genomic DNA by restriction digest. 75 ng of lambda phage DNA that was either
untreated or treated with M.SssI was incubated in the presence of no restriction enzyme (), MspI, or HpaII, with appropriate buffers. While MspI cleaves both unmethylated and
methylated CG-containing sites, HpaII is blocked from cleavage by CG methylation.
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Figure S3-3. ACE-Seq optimization to promote full deamination of λ phage genome
(a) Highlighter plot showing deamination events (red) and non-deamination events (cyan) compared to the nondeaminated master sequence. Clones from experiments without DMSO and with 10% DMSO are shown. Strong
hairpin formation was predicted using secondary structure prediction software from position 363-378, likely
contributing to lack of deamination in this area without DMSO. (b) Highlighter plot showing deamination events
(red) and non-deamination events (cyan) compared to the non-deaminated master sequence. Clones from
experiments performed at 25 ºC, 37 ºC, and under slow ramping conditions are shown.
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Figure S3-5. Comparison of ACE-Seq as a function of gDNA input
(a) Browser snapshot showing base-resolution hmCG (blue) maps near the Neurod6 gene (chr6:55,614,961-55,646,769; mm9).
ACE-Seq raw signals of CpGs on both strands were combined and only CpG dyads sequenced to depth >=2 are shown. Gray
tracks denote sequencing coverage for each CpG dyads. (b) Correlation density plot between ACE-Seq experiments with 2 ng
or 20 ng of DNA as input. Mean ACE-Seq raw signals were calculated for tiled 10-kb bins across the mouse genome.
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Figure S3-6. Relationship of DNA modifications and chromatin states at representative loci.
Browser snapshot showing base-resolution CG (green), mCG (red), hmCG (blue) maps, as well as RNA-Seq, ATAC-Seq, and ChIPSeq of major histone modifications near the (a) transcriptionally active Neurod6 (chr6:55,667,934-55,690,102; mm10) gene and (b)
the inactive Gad2 gene (chr2:22,607,043-22,660,967; mm10). Only CGs sequenced to depth >= 2 are shown. Gray tracks denote
sequencing coverage for each position in the base-resolution map.

91

Figure S3-6. Distribution of C, mC, and hmC levels at representative genomic elements
Ternary plots show the levels of C, mC, and hmC within 1-kb bins overlapping with representative genomic elements.

92

Figure S3-7. Enrichment of high-level hmCG sites
(a) The distribution of abundances of called hmCG (blue) and mCG (red)
at individual sites in cortical excitatory neurons. The dashed line denotes
the signal level of 0.6, the cutoff used to select high-level hmCG sites. (b)
The fraction of high-level hmCG (purple) and all hmCG (yellow) sites
within various genomic elements (relative to total number of CG sites in
each group).
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Figure S3-8. Possible applications of enzymatic deamination for mC localization
(a) Comparison of chemical and enzymatic deamination. Chemical deamination is efficient on C, while mC is
largely resistant to the reaction. Also, hmC is converted to a CMS adduct, while fC is inefficiently deaminated.
Efforts to drive this reaction starts to increase aberrant mC deamination (see Wu et al., Nature Prot, 2016,
11:1081-1100). Enzymatic deamination is efficient on C and mC and discriminates against all ox-mCs (see
Schutsky et al., NAR, 2017, 45:7655-7665.) (b) Schemes for detection of mC. Potential schemes for localizing
mC and all ox-mCs involve TET-mediated oxidation with or without coupled protection with `GT, which
would lead to conversion of C bases only. As another alternative, after bisulfite treatment, A3A can be used to
deaminate mC but not CMS to differentiate hmC and mC, although such a method would suffer from the
limitations of bisulfite.
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Table S3-1. Statistics from whole-genome sequencing runs.
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